reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason
CD012216-bib-0001,"Doraiswamy PM, Clark C, Sperling R, Reiman E, Pontecorvo M, Sabbagh M, et al. ",Prognostic significance of florbetapir F18 PET imaging in MCI and mormal elderly: final results from a longitudinal multicenter trial, Alzheimer's & Dementia ,2011,7 Suppl,    ,['citation-journal']," Doraiswamy PM, Clark C, Sperling R, Reiman E, Pontecorvo M, Sabbagh M, et al. Prognostic significance of florbetapir F18 PET imaging in MCI and mormal elderly: final results from a longitudinal multicenter trial.  Alzheimer's & Dementia 2011;7 Suppl(4):S108. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2011.05.270', 'https://scholar.google.com/scholar_lookup?title=Prognostic+significance+of+florbetapir+F18+PET+imaging+in+MCI+and+mormal+elderly:+final+results+from+a+longitudinal+multicenter+trial+&author=PM+Doraiswamy&author=C+Clark&author=R+Sperling&author=E+Reiman&author=M+Pontecorvo&author=M+Sabbagh&publication_year=2011&hl=en']",,https://doi.org/10.1016/j.jalz.2011.05.270, Doraiswamy 2014 {published data only}  ,included,CD012216-bbs2-0001,
CD012216-bib-0002,"Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. ",Amyloid‐β assessed by florbetapir F 18 PET and 18‐month cognitive decline: a multicenter study, Neurology ,2012,79,    ,['citation-journal']," Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid‐β assessed by florbetapir F 18 PET and 18‐month cognitive decline: a multicenter study.  Neurology 2012;79(16):1636‐44. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1212/WNL.0b013e3182661f74', 'https://www.ncbi.nlm.nih.gov/pubmed/22786606', 'https://scholar.google.com/scholar_lookup?title=Amyloid‐β+assessed+by+florbetapir+F+18+PET+and+18‐month+cognitive+decline:+a+multicenter+study+&author=PM+Doraiswamy&author=RA+Sperling&author=RE+Coleman&author=KA+Johnson&author=EM+Reiman&author=MD+Davis&publication_year=2012&hl=en']",22786606,https://doi.org/10.1212/WNL.0b013e3182661f74, Doraiswamy 2014 {published data only}  ,included,CD012216-bbs2-0001,
CD012216-bib-0003,"Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. ",Florbetapir F 18 amyloid PET and 36‐month cognitive decline: a prospective multicenter study, Molecular Psychiatry ,2014,19,    ,['citation-journal']," Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36‐month cognitive decline: a prospective multicenter study.  Molecular Psychiatry 2014;19(9):1044‐51. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/mp.2014.9', 'https://www.ncbi.nlm.nih.gov/pubmed/24614494', 'https://scholar.google.com/scholar_lookup?title=Florbetapir+F+18+amyloid+PET+and+36‐month+cognitive+decline:+a+prospective+multicenter+study+&author=PM+Doraiswamy&author=RA+Sperling&author=K+Johnson&author=EM+Reiman&author=TZ+Wong&author=MN+Sabbagh&publication_year=2014&hl=en']",24614494,https://doi.org/10.1038/mp.2014.9, Doraiswamy 2014 {published data only}  ,included,CD012216-bbs2-0001,
CD012216-bib-0004,"Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. ","Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging", Alzheimer's & Dementia ,2013,9 Suppl,    ,['citation-journal']," Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.  Alzheimer's & Dementia 2013;9 Suppl(5):S72‐83. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2012.10.007', ""https://scholar.google.com/scholar_lookup?title=Florbetapir+(F18‐AV‐45)+PET+to+assess+amyloid+burden+in+Alzheimer's+disease+dementia,+mild+cognitive+impairment,+and+normal+aging+&author=KA+Johnson&author=RA+Sperling&author=CM+Gidicsin&author=JS+Carmasin&author=JE+Maye&author=RE+Coleman&publication_year=2013&hl=en""]",,https://doi.org/10.1016/j.jalz.2012.10.007, Doraiswamy 2014 {published data only}  ,included,CD012216-bbs2-0001,
CD012216-bib-0005,NCT00857506. ,Observational study of cognitive outcomes for subjects who have had prior PET amyloid imaging With Florbetapir F 18 (18F‐AV‐45),,,,   ,['citation-other'], NCT00857506. Observational study of cognitive outcomes for subjects who have had prior PET amyloid imaging With Florbetapir F 18 (18F‐AV‐45). https://clinicaltrials.gov/show/NCT00857506 (first received 6 March 2009). CENTRAL    ,[''],,, Doraiswamy 2014 {published data only}  ,included,CD012216-bbs2-0001,
CD012216-bib-0006,"Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, et al. ",Amyloid imaging and cognitive decline in nondemented oldest‐old: the 90+ study, Alzheimer's & Dementia ,2013,9,    ,['citation-journal']," Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, et al. Amyloid imaging and cognitive decline in nondemented oldest‐old: the 90+ study.  Alzheimer's & Dementia 2013;9(2):199‐203. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2012.06.005', 'https://scholar.google.com/scholar_lookup?title=Amyloid+imaging+and+cognitive+decline+in+nondemented+oldest‐old:+the+90++study&author=CH+Kawas&author=DE+Greenia&author=SS+Bullain&author=CM+Clark&author=MJ+Pontecorvo&author=AD+Joshi&publication_year=2013&hl=en']",,https://doi.org/10.1016/j.jalz.2012.06.005, Kawas 2013 {published data only}  ,included,CD012216-bbs2-0002,
CD012216-bib-0007,,ADNI 2 PET Technical Procedures Manual AV‐45 (Florbetapir F 18) & FDG,,,,   ,['citation-other'], ADNI 2 PET Technical Procedures Manual AV‐45 (Florbetapir F 18) & FDG. adni.loni.usc.edu/wp‐content/uploads/2010/05/ADNI2_PET_Tech_Manual_0142011.pdf (accessed prior to 12 October 2017). CENTRAL    ,[''],,, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0008,,ADNI‐GOPET Technical Procedures Manual AV‐45 & FDG,,,,   ,['citation-other'], ADNI‐GOPET Technical Procedures Manual AV‐45 & FDG. adni.loni.usc.edu/wp‐content/uploads/2010/05/ADNIGO_PET_Tech_Manual_01142011.pdf (accessed prior to 12 October 2017). CENTRAL    ,[''],,, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0009,,Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2),,,,   ,['citation-other'], Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2). www.adni‐info.org/Scientists/doc/ADNI2_Procedures_Manual_20130624.pdf (accessed prior to 12 October 2017). CENTRAL    ,[''],,, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0010,,Alzheimer’s Disease Neuroimaging Initiative Grand Opportunity (ADNI‐GO),,,,   ,['citation-other'], Alzheimer’s Disease Neuroimaging Initiative Grand Opportunity (ADNI‐GO). www.adni‐info.org/Scientists/doc/ADNI_GO_Procedures_Manual_06102011.pdf (accessed prior to 12 October 2017). CENTRAL    ,[''],,, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0011,NCT01078636. ,Alzheimer's disease neuroimaging initiative grand opportunity (ADNI‐GO),,,,   ,['citation-other'], NCT01078636. Alzheimer's disease neuroimaging initiative grand opportunity (ADNI‐GO). clinicaltrials.gov/show/NCT01078636 (first received 2 March 2010). CENTRAL    ,[''],,, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0012,NCT01231971. ,Alzheimer's disease neuroimaging initiative 2 (ADNI2),,,,   ,['citation-other'], NCT01231971. Alzheimer's disease neuroimaging initiative 2 (ADNI2). clinicaltrials.gov/show/NCT01231971 (first received 1 November 2010). CENTRAL    ,[''],,, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0013,"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative. ",Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes, JAMA Neurology ,2015,72,    ,['citation-journal']," Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative. Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes.  JAMA Neurology 2015;72(10):1183‐90. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jamaneurol.2015.1633', 'https://www.ncbi.nlm.nih.gov/pubmed/26280102', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+visual+and+quantitative+Florbetapir+F+18+positron+emission+tomography+analysis+in+predicting+mild+cognitive+impairment+outcomes+&author=S+Schreiber&author=SM+Landau&author=A+Fero&author=F+Schreiber&author=WJ+Jagust&publication_year=2015&hl=en']",26280102,https://doi.org/10.1001/jamaneurol.2015.1633, Schreiber 2015 {published data only}  ,included,CD012216-bbs2-0003,
CD012216-bib-0014,"Altomare D, Festari C, Ferrari C, Muscio C, Padovani A, Frisoni GB, et al. ",Brain amyloidosis and cognitive decline in MCI: 12‐month follow‐up, Alzheimer's & Dementia ,2016,12,    ,['citation-journal']," Altomare D, Festari C, Ferrari C, Muscio C, Padovani A, Frisoni GB, et al. Brain amyloidosis and cognitive decline in MCI: 12‐month follow‐up.  Alzheimer's & Dementia 2016;12(7 Supplement):P16‐P17. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Brain+amyloidosis+and+cognitive+decline+in+MCI:+12‐month+follow‐up&author=D+Altomare&author=C+Festari&author=C+Ferrari&author=C+Muscio&author=A+Padovani&author=GB+Frisoni&publication_year=2016&hl=en']",,, Altomare 2016 {published data only}  ,excluded,CD012216-bbs2-0004, MCI diagnosis at baseline was not made with any of our accepted definitions by protocol for MCI participants.  Dr Altomare kindly responded to some questions regarding the method of his study (mail received 16/06/2017).  
CD012216-bib-0015,"Apostolova L, Goukasian N, Do T, Grotts J, Ringman J, Elashoff D. ",Effect of brain amyloidosis on the emergence of neuropsychiatric behaviors in MCI over time, Neurology ,2016,86 Suppl 16,    ,['citation-journal']," Apostolova L, Goukasian N, Do T, Grotts J, Ringman J, Elashoff D. Effect of brain amyloidosis on the emergence of neuropsychiatric behaviors in MCI over time.  Neurology 2016;86 Suppl 16:P2.232. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effect+of+brain+amyloidosis+on+the+emergence+of+neuropsychiatric+behaviors+in+MCI+over+time+&author=L+Apostolova&author=N+Goukasian&author=T+Do&author=J+Grotts&author=J+Ringman&author=D+Elashoff&publication_year=2016&hl=en']",,, Apostolova 2016 {published data only}  ,excluded,CD012216-bbs2-0005, Not having data for constructing a 2 x 2 table. The study was focused on the development of neuropsychiatric symptoms and not on Alzheimer's disease or dementia progression.  
CD012216-bib-0016,"Brendel M, Hoegenauer M, Delker A, Bartenstein P, Rominger A. ",Longitudinal amyloid PET in mild cognitive impaired patients, Journal of Nuclear Medicine ,2014,55 Suppl 1,    ,['citation-journal']," Brendel M, Hoegenauer M, Delker A, Bartenstein P, Rominger A. Longitudinal amyloid PET in mild cognitive impaired patients.  Journal of Nuclear Medicine 2014;55 Suppl 1:193. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Longitudinal+amyloid+PET+in+mild+cognitive+impaired+patients&author=M+Brendel&author=M+Hoegenauer&author=A+Delker&author=P+Bartenstein&author=A+Rominger&publication_year=2014&hl=en']",,, Brendel 2014 {published data only}  ,excluded,CD012216-bbs2-0006, Not having data for constructing a 2 x 2 table. The study was focused on longitudinal quantitative analyses of 18F‐florbetapir PET and their association with progression of dementia.  
CD012216-bib-0017,"Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. ",Improved longitudinal [(18)F]‐AV45 amyloid PET by white matter reference and VOI‐based partial volume effect correction, NeuroImage ,2015,108,    ,['citation-journal']," Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]‐AV45 amyloid PET by white matter reference and VOI‐based partial volume effect correction.  NeuroImage 2015;108:450‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.neuroimage.2014.11.055', 'https://www.ncbi.nlm.nih.gov/pubmed/25482269', 'https://scholar.google.com/scholar_lookup?title=Improved+longitudinal+[(18)F]‐AV45+amyloid+PET+by+white+matter+reference+and+VOI‐based+partial+volume+effect+correction+&author=M+Brendel&author=M+Högenauer&author=A+Delker&author=J+Sauerbeck&author=P+Bartenstein&author=J+Seibyl&publication_year=2015&hl=en']",25482269,https://doi.org/10.1016/j.neuroimage.2014.11.055, Brendel 2015 {published data only}  ,excluded,CD012216-bbs2-0007, Not having data for constructing a 2 x 2 table. The study was focused on testing the effects of different reference regions and atrophy‐based partial volume effects on the discriminatory power and longitudinal performance of amyloid PET.  
CD012216-bib-0018,"Cheewakriengkrai L, Manitsirikul S, Mohades S, Wang S, Shin M, Benedet AL, et al. ",Neurodegeneration associated with longitudinal changes of abeta1‐42 and fibrillary amyloid, Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Cheewakriengkrai L, Manitsirikul S, Mohades S, Wang S, Shin M, Benedet AL, et al. Neurodegeneration associated with longitudinal changes of abeta1‐42 and fibrillary amyloid.  Alzheimer's & Dementia 2014;10 Suppl(4):839‐40. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Neurodegeneration+associated+with+longitudinal+changes+of+abeta1‐42+and+fibrillary+amyloid+&author=L+Cheewakriengkrai&author=S+Manitsirikul&author=S+Mohades&author=S+Wang&author=M+Shin&author=AL+Benedet&publication_year=2014&hl=en']",,, Cheewakriengkrai 2014 {published data only}  ,excluded,CD012216-bbs2-0008," Not having data for constructing a 2 x 2 table. The study was focused on the relationship between regional distributions of brain fibrillar amyloid deposition, neurodegenerative biomarkers in CSF (CSF Aβ 1‐42, t‐tau, p‐tau) and cognitive function (ADAS‐cog) at 24 months follow‐up.  "
CD012216-bib-0019,"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. ",Improved power for characterizing longitudinal amyloid‐beta PET changes and evaluating amyloid‐modifying treatments with a cerebral white matter reference region, Journal of Nuclear Medicine ,2015,56,    ,['citation-journal']," Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid‐beta PET changes and evaluating amyloid‐modifying treatments with a cerebral white matter reference region.  Journal of Nuclear Medicine 2015;56(4):560‐66. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2967/jnumed.114.149732', 'https://www.ncbi.nlm.nih.gov/pubmed/25745091', 'https://scholar.google.com/scholar_lookup?title=Improved+power+for+characterizing+longitudinal+amyloid‐beta+PET+changes+and+evaluating+amyloid‐modifying+treatments+with+a+cerebral+white+matter+reference+region+&author=K+Chen&author=A+Roontiva&author=P+Thiyyagura&author=W+Lee&author=X+Liu&author=N+Ayutyanont&publication_year=2015&hl=en']",25745091,https://doi.org/10.2967/jnumed.114.149732, Chen 2015a {published data only}  ,excluded,CD012216-bbs2-0009," Not having data for constructing a 2 x 2 table. The study compared the power of template‐based cerebellar, pontine, and cerebral white matter reference regions to track 24‐month florbetapir standardized uptake value (SUV) ratio (SUVR) changes; and to relate those changes to 24‐month clinical declines  "
CD012216-bib-0020,"Chen X, Wang R, Gao R, Cao H, Wong D, Zhou Y. ",Evaluation of the diagnostic value of FDG and amyloid PET imaging with CSF biomarkers in monitoring the progression in Alzheimer's disease, Journal of Nuclear Medicine ,2015,56 Suppl 3,    ,['citation-journal']," Chen X, Wang R, Gao R, Cao H, Wong D, Zhou Y. Evaluation of the diagnostic value of FDG and amyloid PET imaging with CSF biomarkers in monitoring the progression in Alzheimer's disease.  Journal of Nuclear Medicine 2015;56 Suppl 3:1569. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+diagnostic+value+of+FDG+and+amyloid+PET+imaging+with+CSF+biomarkers+in+monitoring+the+progression+in+Alzheimer's+disease+&author=X+Chen&author=R+Wang&author=R+Gao&author=H+Cao&author=D+Wong&author=Y+Zhou&publication_year=2015&hl=en""]",,, Chen 2015b {published data only}  ,excluded,CD012216-bbs2-0010," Not having data for constructing a 2 x 2 table. The study was focused in the diagnostic potential of FDG PET, florbetapir, PiB and CSF biomarkers in monitoring the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (ADD) and cognitively normal (NC) to MCI in a longitudinal study  "
CD012216-bib-0021,"Chincarini A, Sensi F, Guerra UP, Morbelli S, Bossert I, Rei L, et al. ",Amyloid‐PET quantification: methods and rationale, Clinical and Translational Imaging ,2015,3 Suppl,    ,['citation-journal']," Chincarini A, Sensi F, Guerra UP, Morbelli S, Bossert I, Rei L, et al. Amyloid‐PET quantification: methods and rationale.  Clinical and Translational Imaging 2015;3 Suppl(1):S20. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Amyloid‐PET+quantification:+methods+and+rationale&author=A+Chincarini&author=F+Sensi&author=UP+Guerra&author=S+Morbelli&author=I+Bossert&author=L+Rei&publication_year=2015&hl=en']",,, Chincarini 2015 {published data only}  ,excluded,CD012216-bbs2-0011, Not having data for constructing a 2 x 2 table. The study was focused on examining different approaches to amyloid‐PET quantification and a longitudinal analyses of Aβ deposition.  
CD012216-bib-0022,"Chincarini A, Sensi F, Rei L, Bossert I, Morbelli S, Guerra UP, et al. ",Standardized uptake value ratio‐independent evaluation of brain amyloidosis, Journal of Alzheimer's Disease ,2016,54,    ,['citation-journal']," Chincarini A, Sensi F, Rei L, Bossert I, Morbelli S, Guerra UP, et al. Standardized uptake value ratio‐independent evaluation of brain amyloidosis.  Journal of Alzheimer's Disease 2016;54(4):1437‐57. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3233/JAD-160232', 'https://www.ncbi.nlm.nih.gov/pubmed/27662288', 'https://scholar.google.com/scholar_lookup?title=Standardized+uptake+value+ratio‐independent+evaluation+of+brain+amyloidosis&author=A+Chincarini&author=F+Sensi&author=L+Rei&author=I+Bossert&author=S+Morbelli&author=UP+Guerra&publication_year=2016&hl=en']",27662288,https://doi.org/10.3233/JAD-160232, Chincarini 2016 {published data only}  ,excluded,CD012216-bbs2-0012," The study focused on the evaluation of brain amyloidosis (ELBA) with a new method on imaging of the 18F‐florbetapir PET scan.  We did not include this study because we preferred to include the Schreiber study for the following reasons:     There was a high risk of duplication of participants with the Schreiber study, due to both studies using the same ADNI database.    The Schreiber study had more participants: 401 MCI participants compared to 62 in the Chincarini study.    The reason why there were no participants with MCI at baseline who maintained their condition at the follow‐up was not clear.     "
CD012216-bib-0023,"Durcanova B, Diaz‐Aguilar D, Parker E, Lee J, Yi L, Silverman D. ",Optimal strategies for using amyloid imaging and FDG PET in prognostic evaluation of mild cognitive impairment (MCI), Journal of Nuclear Medicine ,2015,56 Suppl 3,    ,['citation-journal']," Durcanova B, Diaz‐Aguilar D, Parker E, Lee J, Yi L, Silverman D. Optimal strategies for using amyloid imaging and FDG PET in prognostic evaluation of mild cognitive impairment (MCI).  Journal of Nuclear Medicine 2015;56 Suppl 3:192. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Optimal+strategies+for+using+amyloid+imaging+and+FDG+PET+in+prognostic+evaluation+of+mild+cognitive+impairment+(MCI)+&author=B+Durcanova&author=D+Diaz‐Aguilar&author=E+Parker&author=J+Lee&author=L+Yi&author=D+Silverman&publication_year=2015&hl=en']",,, Durkanova 2015 {published data only}  ,excluded,CD012216-bbs2-0013, Not having data for constructing a 2 x 2 table. The study was focused in evaluate five different test strategies for integrating use of florbetapir and FDG PET information to predict rates of cognitive and functional decline over 2 years.  
CD012216-bib-0024,"Fan Z, Harold D, Pasqualetti G, Williams J, Brooks DJ, Edison P. ",Can studies of neuroinflammation in a TSPO genetic subgroup (HAB or MAB) be applied to the entire AD cohort?, Journal of Nuclear Medicine ,2015,56,    ,['citation-journal']," Fan Z, Harold D, Pasqualetti G, Williams J, Brooks DJ, Edison P. Can studies of neuroinflammation in a TSPO genetic subgroup (HAB or MAB) be applied to the entire AD cohort?.  Journal of Nuclear Medicine 2015;56(5):707‐13. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2967/jnumed.114.149443', 'https://www.ncbi.nlm.nih.gov/pubmed/25840980', 'https://scholar.google.com/scholar_lookup?title=Can+studies+of+neuroinflammation+in+a+TSPO+genetic+subgroup+(HAB+or+MAB)+be+applied+to+the+entire+AD+cohort?+&author=Z+Fan&author=D+Harold&author=G+Pasqualetti&author=J+Williams&author=DJ+Brooks&author=P+Edison&publication_year=2015&hl=en']",25840980,https://doi.org/10.2967/jnumed.114.149443, Fan 2015 {published data only}  ,excluded,CD012216-bbs2-0014," Not having data for constructing a 2 x 2 table. The study was focused on investigating whether different translocator protein genotypes influenced cognitive function, amyloid load, and disease progression over time.  "
CD012216-bib-0025,"Greenia D, Kawas C, Caunca M, Bullain S, Corrada M. ",PET amyloid imaging with florbetapir predicts cognitive decline in the oldest‐old, Neurology ,2014,82 Suppl 10,    ,['citation-journal']," Greenia D, Kawas C, Caunca M, Bullain S, Corrada M. PET amyloid imaging with florbetapir predicts cognitive decline in the oldest‐old.  Neurology 2014;82 Suppl 10:P4.011. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=PET+amyloid+imaging+with+florbetapir+predicts+cognitive+decline+in+the+oldest‐old&author=D+Greenia&author=C+Kawas&author=M+Caunca&author=S+Bullain&author=M+Corrada&publication_year=2014&hl=en']",,, Greenia 2014 {published data only}  ,excluded,CD012216-bbs2-0015, Not having data for constructing a 2 x 2 table. The study was focused on evaluating the 18F‐florbetapir PET and the relationship with cognitive decline in the oldest‐old.  
CD012216-bib-0026,"Hochstetler H, Wang S, Yu P, Trzepacz PT, Case M, Henley D, et al. ",Empirically defining trajectories of late‐life cognitive and functional decline, Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Hochstetler H, Wang S, Yu P, Trzepacz PT, Case M, Henley D, et al. Empirically defining trajectories of late‐life cognitive and functional decline.  Alzheimer's & Dementia 2014;10 Suppl(4):687‐8. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2014.05.1250', 'https://scholar.google.com/scholar_lookup?title=Empirically+defining+trajectories+of+late‐life+cognitive+and+functional+decline&author=H+Hochstetler&author=S+Wang&author=P+Yu&author=PT+Trzepacz&author=M+Case&author=D+Henley&publication_year=2014&hl=en']",,https://doi.org/10.1016/j.jalz.2014.05.1250, Hochstetler 2014 {published data only}  ,excluded,CD012216-bbs2-0016," Not having data for constructing a 2 x 2 table. The study was focused on trying to define trajectories of cognitive and functional decline, and characteristics associated with distinct trajectories, using Growth Mixture Modeling.  "
CD012216-bib-0027,"Joshi A, Pontecorvo M, Navitsky MA, Kennedy IA, Mintun M, Devous MD. ",Measuring change in beta‐amyloid burden over time using florbetapir‐PET and a subcortical white matter reference region, Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Joshi A, Pontecorvo M, Navitsky MA, Kennedy IA, Mintun M, Devous MD. Measuring change in beta‐amyloid burden over time using florbetapir‐PET and a subcortical white matter reference region.  Alzheimer's & Dementia 2014;10 Suppl(4):902. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2014.07.087', 'https://scholar.google.com/scholar_lookup?title=Measuring+change+in+beta‐amyloid+burden+over+time+using+florbetapir‐PET+and+a+subcortical+white+matter+reference+region+&author=A+Joshi&author=M+Pontecorvo&author=MA+Navitsky&author=IA+Kennedy&author=M+Mintun&author=MD+Devous&publication_year=2014&hl=en']",,https://doi.org/10.1016/j.jalz.2014.07.087, Joshi 2014 {published data only}  ,excluded,CD012216-bbs2-0017, Not having data for constructing a 2 x 2 table. The study was focused on the estimation of longitudinal change in Aβ burden over 2 years.  
CD012216-bib-0028,"Klein G, Sampat M, Staewen D, Scott D, Suhy J. ",Comparison of SUVR methods and reference regions in amyloid PET, Journal of Nuclear Medicine ,2015,56 Suppl 3,    ,['citation-journal']," Klein G, Sampat M, Staewen D, Scott D, Suhy J. Comparison of SUVR methods and reference regions in amyloid PET.  Journal of Nuclear Medicine 2015;56 Suppl 3:1741. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+SUVR+methods+and+reference+regions+in+amyloid+PET&author=G+Klein&author=M+Sampat&author=D+Staewen&author=D+Scott&author=J+Suhy&publication_year=2015&hl=en']",,, Klein 2015 {published data only}  ,excluded,CD012216-bbs2-0018, Not having data for constructing a 2 x 2 table. The study was focused on the evaluation of native space compared to SPM template methods and a variety of possible SUVR reference regions with highest longitudinal change in the SUVR at 24 months.  
CD012216-bib-0029,"Landau S, Fero A, Baker S, Jagust W. ",Modeling longitudian Florbetapir change across the disease spectrum, Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Landau S, Fero A, Baker S, Jagust W. Modeling longitudian Florbetapir change across the disease spectrum.  Alzheimer's & Dementia 2014;10 Suppl(4):P7. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Modeling+longitudian+Florbetapir+change+across+the+disease+spectrum&author=S+Landau&author=A+Fero&author=S+Baker&author=W+Jagust&publication_year=2014&hl=en']",,, Landau 2014 {published data only}  ,excluded,CD012216-bbs2-0019," Not having data for constructing a 2 x 2 table. The study was focused on the 18F‐florbetapir PET longitudinal evaluation in cognitively normal, MCI, and ADD participants, examining characteristics of normal individuals with subthreshold florbetapir retention and the influence of reference region selection on estimated trajectories across the entire range of amyloid measurements.  "
CD012216-bib-0030,"Landau SM, Horng A, Fero A, Jagust WJ. ",Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI, Neurology ,2016,86,    ,['citation-journal']," Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.  Neurology 2016;86(15):1377‐85. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1212/WNL.0000000000002576', 'https://www.ncbi.nlm.nih.gov/pubmed/26968515', 'https://scholar.google.com/scholar_lookup?title=Amyloid+negativity+in+patients+with+clinically+diagnosed+Alzheimer+disease+and+MCI&author=SM+Landau&author=A+Horng&author=A+Fero&author=WJ+Jagust&publication_year=2016&hl=en']",26968515,https://doi.org/10.1212/WNL.0000000000002576, Landau 2016 {published data only}  ,excluded,CD012216-bbs2-0020," This study was focused on comparing participants with amyloid beta negative MCI and participants with ADD enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) with their Aβ amyloid positive counterparts on a number of clinical, neuropsychological, and biomarker characteristics with an average available follow‐up time for longitudinal cognitive measurements of 1.4 + 0.8 years.  The conversion rate in those MCI participants with PET negative was 11% and the conversion in those with PET positive was 45%.  We did not include this study, and we preferred Schreiber 2015 to be included for the following reasons:     There was a high risk of duplication of participants with the Schreiber study, due to the use of the same ADNI database and Landau was the second author of the Schreiber study.    The Schreiber study had more participants: 401 MCI participants compared to 217 in the Landau study.    The follow‐up was longer in the Schreiber study: 1.6 + 0.7 years and in the Landau study it was 1.4 + 0.8 years.     "
CD012216-bib-0031,"Lee J, Torosyan N, Dahlbom M, Silverman D. ",Amyloid imaging and FDG PET as predictors of subsequent cognitive decline in MCI subpopulation, Journal of Nuclear Medicine ,2015,56 Suppl 3,    ,['citation-journal']," Lee J, Torosyan N, Dahlbom M, Silverman D. Amyloid imaging and FDG PET as predictors of subsequent cognitive decline in MCI subpopulation.  Journal of Nuclear Medicine 2015;56 Suppl 3:190. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Amyloid+imaging+and+FDG+PET+as+predictors+of+subsequent+cognitive+decline+in+MCI+subpopulation&author=J+Lee&author=N+Torosyan&author=M+Dahlbom&author=D+Silverman&publication_year=2015&hl=en']",,, Lee 2015 {published data only}  ,excluded,CD012216-bbs2-0021, Not having data for constructing a 2 x 2 table. This study was focused in the correlation between florbetapir and FDG PET and cognition measured by MMSE at follow‐up.  
CD012216-bib-0032,"Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. ",Effect of amyloid on memory and non‐memory decline from preclinical to clinical Alzheimer's disease, Brain ,2014,137,    ,['citation-journal']," Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Effect of amyloid on memory and non‐memory decline from preclinical to clinical Alzheimer's disease.  Brain 2014;137(1):221‐31. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/brain/awt286', 'https://www.ncbi.nlm.nih.gov/pubmed/24176981', ""https://scholar.google.com/scholar_lookup?title=Effect+of+amyloid+on+memory+and+non‐memory+decline+from+preclinical+to+clinical+Alzheimer's+disease+&author=YY+Lim&author=P+Maruff&author=RH+Pietrzak&author=D+Ames&author=KA+Ellis&author=K+Harrington&publication_year=2014&hl=en""]",24176981,https://doi.org/10.1093/brain/awt286, Lim 2014 {published data only}  ,excluded,CD012216-bbs2-0022, Not having data for constructing a 2 x 2 table. This study was focused on evaluating the florbetapir status at baseline and different cognitive composite measures at 36 months.  
CD012216-bib-0033,"Manitsirikul S, Mathotaarachchi SS, Mohamedes S, Gauthier S, Beaudry T, Rosa‐Neto P. ",How to follow up and cluster subjects by longitudinal changes of fibrillary amyloid imaging and CSF biomarkers? A 24‐month follow up, Alzheimer's & Dementia ,2015,11 Suppl,    ,['citation-journal']," Manitsirikul S, Mathotaarachchi SS, Mohamedes S, Gauthier S, Beaudry T, Rosa‐Neto P. How to follow up and cluster subjects by longitudinal changes of fibrillary amyloid imaging and CSF biomarkers? A 24‐month follow up.  Alzheimer's & Dementia 2015;11 Suppl(7):P19‐21. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=How+to+follow+up+and+cluster+subjects+by+longitudinal+changes+of+fibrillary+amyloid+imaging+and+CSF+biomarkers?+A+24‐month+follow+up+&author=S+Manitsirikul&author=SS+Mathotaarachchi&author=S+Mohamedes&author=S+Gauthier&author=T+Beaudry&author=P+Rosa‐Neto&publication_year=2015&hl=en']",,, Manitsirikul 2015 {published data only}  ,excluded,CD012216-bbs2-0023," Not having data for constructing a 2 x 2 table. The study was focused on the relationship between regional distributions of brain fibrillar amyloid deposition, neurodegenerative biomarkers in brain (FDG) and CSF (tau), brain structural change, and cognitive function at 24‐month follow‐up.  "
CD012216-bib-0034,"Margolin RA, Andrews RD, Lukic AS, Zhao X, Tudor IC, Salloway S, et al. ",Biomarkers and cognition in amyloid positive and amyloid‐negative ADNI‐2 MCI subjects: implications for AD therapeutic trials," Journal of Nutrition, Health & Aging ",2013,17,    ,['citation-journal']," Margolin RA, Andrews RD, Lukic AS, Zhao X, Tudor IC, Salloway S, et al. Biomarkers and cognition in amyloid positive and amyloid‐negative ADNI‐2 MCI subjects: implications for AD therapeutic trials.  Journal of Nutrition, Health & Aging 2013;17(9):795‐96. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Biomarkers+and+cognition+in+amyloid+positive+and+amyloid‐negative+ADNI‐2+MCI+subjects:+implications+for+AD+therapeutic+trials+&author=RA+Margolin&author=RD+Andrews&author=AS+Lukic&author=X+Zhao&author=IC+Tudor&author=S+Salloway&publication_year=2013&hl=en']",,, Margolin 2013 {published data only}  ,excluded,CD012216-bbs2-0024, Not having data for constructing a 2 x 2 table. The study was focused on evaluating the 18F‐florbetapir PET and the relationship with cognitive decline at follow‐up.  
CD012216-bib-0035,"Mathotaarachchi SS, Mohades S, Shin M, Beaudry T, Benedet AL, Pascoal TA, et al. ",Should a global or a regional measure of amyloidosis be used in a longitudinal study?, Alzheimer's & Dementia ,2015,11 Suppl,    ,['citation-journal']," Mathotaarachchi SS, Mohades S, Shin M, Beaudry T, Benedet AL, Pascoal TA, et al. Should a global or a regional measure of amyloidosis be used in a longitudinal study?.  Alzheimer's & Dementia 2015;11 Suppl(7):P19. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Should+a+global+or+a+regional+measure+of+amyloidosis+be+used+in+a+longitudinal+study?&author=SS+Mathotaarachchi&author=S+Mohades&author=M+Shin&author=T+Beaudry&author=AL+Benedet&author=TA+Pascoal&publication_year=2015&hl=en']",,, Mathotaarachchi 2015 {published data only}  ,excluded,CD012216-bbs2-0025, Not having data for constructing a 2 x 2 table. The study was focused on the regional effects of amyloid retention measured by the 18F‐florbetapir PET scan on the rate of hypometabolism measured by FDG PET scan over the follow‐up.  
CD012216-bib-0036,"Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. ",Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease, Annals of Clinical and Translational Neurology ,2014,1,    ,['citation-journal']," Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease.  Annals of Clinical and Translational Neurology 2014;1(8):534‐43. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/acn3.81', 'https://www.ncbi.nlm.nih.gov/pubmed/25356425', ""https://scholar.google.com/scholar_lookup?title=Diagnostic+accuracy+of+CSF+Ab42+and+florbetapir+PET+for+Alzheimer's+disease&author=N+Mattsson&author=PS+Insel&author=S+Landau&author=W+Jagust&author=M+Donohue&author=LM+Shaw&publication_year=2014&hl=en""]",25356425,https://doi.org/10.1002/acn3.81, Mattsson 2014a {published data only}  ,excluded,CD012216-bbs2-0026," This study was focused on comparing the diagnostic test accuracy with CSF Aβ42 and the 18F‐florbetapir PET scan in three different groups, healthy controls, Alzheimer's disease dementia, and MCI (progressive vs stable MCI) participants.  We did not include this study, as we preferred Schreiber 2015 to be included for the following reasons:     There was a high risk of duplication of participants with the Schreiber study, due to both studies using the same ADNI database and two authors from the Schreiber study (Landau and Jagust) also worked in the Mattsson study.    The Schreiber study had more participants, 401 MCI participants compared to 224 in the Mattson study.    The follow‐up was similar: Schreiber study: 1.6 + 0.7 years; Mattsson study: in those with stable MCI, the follow‐up was 2.2 + 0.3 years and in those with progressive MCI, the follow‐up was 1.7 + 0.6 years.     "
CD012216-bib-0037,"Mattsson N, Insel P, Landau S, Jagust W, Shaw L, Trojanowski JQ, et al. ","Combining CSF AB42 and PET florbetapir to predict diagnosis, tau, atrophy, and cognition", Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Mattsson N, Insel P, Landau S, Jagust W, Shaw L, Trojanowski JQ, et al. Combining CSF AB42 and PET florbetapir to predict diagnosis, tau, atrophy, and cognition.  Alzheimer's & Dementia 2014;10 Suppl(4):P174. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2014.04.185', 'https://scholar.google.com/scholar_lookup?title=Combining+CSF+AB42+and+PET+florbetapir+to+predict+diagnosis,+tau,+atrophy,+and+cognition&author=N+Mattsson&author=P+Insel&author=S+Landau&author=W+Jagust&author=L+Shaw&author=JQ+Trojanowski&publication_year=2014&hl=en']",,https://doi.org/10.1016/j.jalz.2014.04.185, Mattsson 2014b {published data only}  ,excluded,CD012216-bbs2-0027," Not having data for constructing a 2 x 2 table. This study was focused in determine the extent to which CSF and 18F‐florbetapir PET contribute independent diagnostic information in AD studies, and to determine the nature and degree of pathology in discordantly classified individuals in healthy controls, ADD patients, and MCI participants.  "
CD012216-bib-0038,"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. ",Independent information from cerebrospinal fluid amyloid‐β and florbetapir imaging in Alzheimer's disease, Brain ,2015,138,    ,['citation-journal']," Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid‐β and florbetapir imaging in Alzheimer's disease.  Brain 2015;138(3):772‐83. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/brain/awu367', 'https://www.ncbi.nlm.nih.gov/pubmed/25541191', ""https://scholar.google.com/scholar_lookup?title=Independent+information+from+cerebrospinal+fluid+amyloid‐β+and+florbetapir+imaging+in+Alzheimer's+disease+&author=N+Mattsson&author=PS+Insel&author=M+Donohue&author=S+Landau&author=WJ+Jagust&author=LM+Shaw&publication_year=2015&hl=en""]",25541191,https://doi.org/10.1093/brain/awu367, Mattsson 2015a {published data only}  ,excluded,CD012216-bbs2-0028," Not having data for constructing a 2 x 2 table. The study was focused on testing if CSF and amyloid beta PET scan biomarkers were independently related to other Alzheimer's disease markers, and to examine individuals who were discordantly classified by these two biomarker modalities with a follow‐up for up to three years.  "
CD012216-bib-0039,"Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M, et al. ",Brain structure and function as mediators of the effects of amyloid on memory, Neurology ,2015,84,    ,['citation-journal']," Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M, et al. Brain structure and function as mediators of the effects of amyloid on memory.  Neurology 2015;84(11):1136‐44. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1212/WNL.0000000000001375', 'https://www.ncbi.nlm.nih.gov/pubmed/25681451', 'https://scholar.google.com/scholar_lookup?title=Brain+structure+and+function+as+mediators+of+the+effects+of+amyloid+on+memory&author=N+Mattsson&author=PS+Insel&author=PS+Aisen&author=W+Jagust&author=S+Mackin&author=M+Weiner&publication_year=2015&hl=en']",25681451,https://doi.org/10.1212/WNL.0000000000001375, Mattsson 2015b {published data only}  ,excluded,CD012216-bbs2-0029, Not having data for constructing a 2 x 2 table. The study was focused on relationships in a large number of brain regions in MCI participants with cognitive evaluations for up to three years with Logical Memory delayed recall and Rey Auditory Verbal Learning Test delayed recall.  
CD012216-bib-0040,"Lu M, Pontecorvo MJ, Siderowf A, Joshi AD, Devous MD, Mintun MA, et al. ",Prognostic value of 18F‐Florbetapir scan: a 36‐month follow up analysis using ADNI data, Clinical and Translational Imaging ,2015,3 Suppl 1,    ,['citation-journal']," Lu M, Pontecorvo MJ, Siderowf A, Joshi AD, Devous MD, Mintun MA, et al. Prognostic value of 18F‐Florbetapir scan: a 36‐month follow up analysis using ADNI data.  Clinical and Translational Imaging 2015;3 Suppl 1:S126. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Prognostic+value+of+18F‐Florbetapir+scan:+a+36‐month+follow+up+analysis+using+ADNI+data+&author=M+Lu&author=MJ+Pontecorvo&author=A+Siderowf&author=AD+Joshi&author=MD+Devous&author=MA+Mintun&publication_year=2015&hl=en']",,, Ming 2015 {published data only}  ,excluded,CD012216-bbs2-0030," Not having data for constructing a 2 x 2 table. The study was focused on MCI participants and 18F‐florbetapir at baseline and follow‐up for up to three years with cognitive evaluations with MMSE, ADAS11 and CDR sum of boxes.  "
CD012216-bib-0041,"Mohades S, Mathotaarachchi SS, Parent M, Shin M, Wang S, Benedet AL, et al. ",Neurodegeneration and cortical atrophy in [18f] florbetapir accumulators and non‐accumulators, Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Mohades S, Mathotaarachchi SS, Parent M, Shin M, Wang S, Benedet AL, et al. Neurodegeneration and cortical atrophy in [18f] florbetapir accumulators and non‐accumulators.  Alzheimer's & Dementia 2014;10 Suppl(4):P26‐7. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2014.05.047', 'https://scholar.google.com/scholar_lookup?title=Neurodegeneration+and+cortical+atrophy+in+[18f]+florbetapir+accumulators+and+non‐accumulators&author=S+Mohades&author=SS+Mathotaarachchi&author=M+Parent&author=M+Shin&author=S+Wang&author=AL+Benedet&publication_year=2014&hl=en']",,https://doi.org/10.1016/j.jalz.2014.05.047, Mohades 2014 {published data only}  ,excluded,CD012216-bbs2-0031, Not having data for constructing a 2 x 2 table. The study was focused on comparing neurodegeneration in 18F‐florbetapir accumulators and nonaccumulators based on a 24‐month assessment.  
CD012216-bib-0042,"Morbelli S, Nobili F, Sensi F, Guerra U, Rei L, Bossert I, et al. ",SUVratio (SUVr)‐independent semiquantification of brain amyloidosis: a software‐aided integration of visual and quantitative analyses, European Journal of Nuclear Medicine and Molecular Imaging ,2015,42 Suppl 1,    ,['citation-journal']," Morbelli S, Nobili F, Sensi F, Guerra U, Rei L, Bossert I, et al. SUVratio (SUVr)‐independent semiquantification of brain amyloidosis: a software‐aided integration of visual and quantitative analyses.  European Journal of Nuclear Medicine and Molecular Imaging 2015;42 Suppl 1:S547. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=SUVratio+(SUVr)‐independent+semiquantification+of+brain+amyloidosis:+a+software‐aided+integration+of+visual+and+quantitative+analyses+&author=S+Morbelli&author=F+Nobili&author=F+Sensi&author=U+Guerra&author=L+Rei&author=I+Bossert&publication_year=2015&hl=en']",,, Morbelli 2015 {published data only}  ,excluded,CD012216-bbs2-0032, Not having data for constructing a 2 x 2 table. The study was focused on MCI participants that had longitudinal evaluation with the 18F‐florbetapir PET scan over two years and different methods to establish the PET positivity.  
CD012216-bib-0043,"Pascoal T, Benedet A, Mathotaarachchi S, Soucy JP, Beaudry T, Gauthier S, et al. ",Amyloidbeta and hyperphosphorylated tau synergy drives clinical progression in individuals with mild cognitive impairment, Neurology ,2016,86 Suppl,    ,['citation-journal']," Pascoal T, Benedet A, Mathotaarachchi S, Soucy JP, Beaudry T, Gauthier S, et al. Amyloidbeta and hyperphosphorylated tau synergy drives clinical progression in individuals with mild cognitive impairment.  Neurology 2016;86 Suppl(16):P2.228. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Amyloidbeta+and+hyperphosphorylated+tau+synergy+drives+clinical+progression+in+individuals+with+mild+cognitive+impairment+&author=T+Pascoal&author=A+Benedet&author=S+Mathotaarachchi&author=JP+Soucy&author=T+Beaudry&author=S+Gauthier&publication_year=2016&hl=en']",,, Pascoal 2016 {published data only}  ,excluded,CD012216-bbs2-0033, Not having data for constructing a 2 x 2 table. The study was focused on neuropsychological and clinical decline in participants with MCI and if they were associated with brain amyloid‐beta deposition and tau hyperphosphorylation.  
CD012216-bib-0044,"Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, et al. ",Synergistic interaction between amyloid and tau predicts the progression to dementia, Alzheimer's & Dementia ,2017,13,    ,['citation-journal']," Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, et al. Synergistic interaction between amyloid and tau predicts the progression to dementia.  Alzheimer's & Dementia 2017;13:644‐53. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2016.11.005', 'https://scholar.google.com/scholar_lookup?title=Synergistic+interaction+between+amyloid+and+tau+predicts+the+progression+to+dementia&author=TA+Pascoal&author=S+Mathotaarachchi&author=M+Shin&author=AL+Benedet&author=S+Mohades&author=S+Wang&publication_year=2017&hl=en']",,https://doi.org/10.1016/j.jalz.2016.11.005, Pascoal 2017 {published data only}  ,excluded,CD012216-bbs2-0034, The study was focused on amnestic MCI individuals and whether the synergism between Aβ aggregation and tau hyperphosphorylation could determine the progression from amnestic MCI to ADD dementia.  We did not include this study because we preferred the Schreiber study to be included for the following reasons:     They used the same ADNI database and 279 of 314 MCI participants in Pascoal 2017 were also included in Schreiber 2015.    The Schreiber study had more participants: 401 MCI participants compared to 314 in the Pascoal study.     Dr Pascoal kindly responded to some questions regarding the method of his study and provided the ADNI identification code of the participants (mail received 16/06/2017).  
CD012216-bib-0045,"Pontecorvo MJ, Joshi A, Skovronsky D, Clark C, Mintun M. ","Florbetapir PET correlates with cognitive decline, PiB PET and CSF markers in the ADNI database", Alzheimer's & Dementia ,2011,7 Suppl,    ,['citation-journal']," Pontecorvo MJ, Joshi A, Skovronsky D, Clark C, Mintun M. Florbetapir PET correlates with cognitive decline, PiB PET and CSF markers in the ADNI database.  Alzheimer's & Dementia 2011;7 Suppl(4):S697. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jalz.2011.05.2014', 'https://scholar.google.com/scholar_lookup?title=Florbetapir+PET+correlates+with+cognitive+decline,+PiB+PET+and+CSF+markers+in+the+ADNI+database+&author=MJ+Pontecorvo&author=A+Joshi&author=D+Skovronsky&author=C+Clark&author=M+Mintun&publication_year=2011&hl=en']",,https://doi.org/10.1016/j.jalz.2011.05.2014, Pontecorvo 2011 {published data only}  ,excluded,CD012216-bbs2-0035," Not having data for constructing a 2 x 2 table. The study was focused on the evaluation of the correlation of florbetapir SUVR with cognitive change from baseline to month 24 in MCI and cognitively normal participants, PET PiB, and CSF amyloid and tau levels.  "
CD012216-bib-0046,"Risacher SL, Kim S, Nho KT, West JD, Petersen RC, Aisen PS, et al. ","Two‐year longitudinal change in amyloid deposition, glucose metabolism, and hippocampal atrophy in ADNI‐2 participants: relation to genetic risk", Alzheimer's & Dementia ,2014,10 Suppl,    ,['citation-journal']," Risacher SL, Kim S, Nho KT, West JD, Petersen RC, Aisen PS, et al. Two‐year longitudinal change in amyloid deposition, glucose metabolism, and hippocampal atrophy in ADNI‐2 participants: relation to genetic risk.  Alzheimer's & Dementia 2014;10 Suppl(4):P211‐12. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Two‐year+longitudinal+change+in+amyloid+deposition,+glucose+metabolism,+and+hippocampal+atrophy+in+ADNI‐2+participants:+relation+to+genetic+risk+&author=SL+Risacher&author=S+Kim&author=KT+Nho&author=JD+West&author=RC+Petersen&author=PS+Aisen&publication_year=2014&hl=en']",,, Risacher 2014 {published data only}  ,excluded,CD012216-bbs2-0036," Not having data for constructing a 2 x 2 table. The study was focused on the comparative assessment of two‐year change in amyloid deposition, glucose metabolism, and hippocampal atrophy in healthy controls, MCI and ADD participants.  "
CD012216-bib-0047,"Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. ",Reference tissue normalization in longitudinal (18)F‐florbetapir positron emission tomography of late mild cognitive impairment, Alzheimer's Research & Therapy ,2016,8,    ,['citation-journal']," Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. Reference tissue normalization in longitudinal (18)F‐florbetapir positron emission tomography of late mild cognitive impairment.  Alzheimer's Research & Therapy 2016;8(1):article no 2. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s13195-016-0172-3', 'https://www.ncbi.nlm.nih.gov/pubmed/26768154', 'https://scholar.google.com/scholar_lookup?title=Reference+tissue+normalization+in+longitudinal+(18)F‐florbetapir+positron+emission+tomography+of+late+mild+cognitive+impairment+&author=S+Shokouhi&author=JW+Mckay&author=SL+Baker&author=H+Kang&author=AB+Brill&author=HE+Gwirtsman&publication_year=2016&hl=en']",26768154,https://doi.org/10.1186/s13195-016-0172-3, Shokouhi 2016 {published data only}  ,excluded,CD012216-bbs2-0037, Not having data for constructing a 2 x 2 table. The study was focused on evaluating the effect of reference tissue normalization in a test–retest 18F‐florbetapir SUVR study using different reference regions and evaluating the correlation between 18F‐florbetapir PET and concurrent CSF Aβ1–42 levels in a MCI cohort over the course of 2 years.  
CD012216-bib-0048,"Siderowf A, Joshi A, Lu M, Mintun M, Pontecorvo M. ",Lack of substantial progression of cognitive deficits in patients with negative amyloid imaging: implications for clinical trials, Neurology ,2013,80 Suppl,    ,['citation-journal']," Siderowf A, Joshi A, Lu M, Mintun M, Pontecorvo M. Lack of substantial progression of cognitive deficits in patients with negative amyloid imaging: implications for clinical trials.  Neurology 2013;80 Suppl(7):P01.016. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lack+of+substantial+progression+of+cognitive+deficits+in+patients+with+negative+amyloid+imaging:+implications+for+clinical+trials+&author=A+Siderowf&author=A+Joshi&author=M+Lu&author=M+Mintun&author=M+Pontecorvo&publication_year=2013&hl=en']",,, Siderowf 2013 {published data only}  ,excluded,CD012216-bbs2-0038, Not having data for constructing a 2 x 2 table. The study was focused on evaluating cognitive decline measured by ADAS‐cog in participants with negative and positive 18F‐florbetapir PET scan imaging with a clinical follow‐up of 18 months.  
CD012216-bib-0049,"Teipel SJ, Kurth J, Krause B, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative. ",The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment ‐ beyond classical regression, NeuroImage: Clinical ,2015,8,    ,['citation-journal']," Teipel SJ, Kurth J, Krause B, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment ‐ beyond classical regression.  NeuroImage: Clinical 2015;8:583‐93. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.nicl.2015.05.006', 'https://www.ncbi.nlm.nih.gov/pubmed/26199870', ""https://scholar.google.com/scholar_lookup?title=The+relative+importance+of+imaging+markers+for+the+prediction+of+Alzheimer's+disease+dementia+in+mild+cognitive+impairment+‐+beyond+classical+regression+&author=SJ+Teipel&author=J+Kurth&author=B+Krause&author=MJ+Grothe&publication_year=2015&hl=en""]",26199870,https://doi.org/10.1016/j.nicl.2015.05.006, Teipel 2015 {published data only}  ,excluded,CD012216-bbs2-0039," Not having data for constructing a 2 x 2 table. The study was focused on comparing penalized regression analysis, with more classical unregularised regression models in respect to predicting conversion from MCI to ADD in 127 MCI subjects who had a clinical follow‐up between 6 and 31 months.  "
CD012216-bib-0050,"Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, et al. ",Nonlinear association between cerebrospinal fluid and florbetapir F‐18 beta‐amyloid measures across the spectrum of Alzheimer disease, JAMA Neurology ,2015,72,    ,['citation-journal']," Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, et al. Nonlinear association between cerebrospinal fluid and florbetapir F‐18 beta‐amyloid measures across the spectrum of Alzheimer disease.  JAMA Neurology 2015;72(5):571‐81. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jamaneurol.2014.4829', 'https://www.ncbi.nlm.nih.gov/pubmed/25822737', 'https://scholar.google.com/scholar_lookup?title=Nonlinear+association+between+cerebrospinal+fluid+and+florbetapir+F‐18+beta‐amyloid+measures+across+the+spectrum+of+Alzheimer+disease+&author=JB+Toledo&author=M+Bjerke&author=X+Da&author=SM+Landau&author=NL+Foster&author=W+Jagust&publication_year=2015&hl=en']",25822737,https://doi.org/10.1001/jamaneurol.2014.4829, Toledo 2015 {published data only}  ,excluded,CD012216-bbs2-0040, Not having data for constructing a 2 x 2 table. The study was focused on determining the association between CSF and PET amyloid biomarkers (cross‐sectional and longitudinal measures) and comparing the cut‐offs for these measures.  
CD012216-bib-0051,"Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, et al. ",Suspected non‐AD pathology in mild cognitive impairment, Neurobiology of Aging ,2015,36,    ,['citation-journal']," Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, et al. Suspected non‐AD pathology in mild cognitive impairment.  Neurobiology of Aging 2015;36(12):3152‐62. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.neurobiolaging.2015.08.029', 'https://www.ncbi.nlm.nih.gov/pubmed/26422359', 'https://scholar.google.com/scholar_lookup?title=Suspected+non‐AD+pathology+in+mild+cognitive+impairment&author=LE+Wisse&author=N+Butala&author=SR+Das&author=C+Davatzikos&author=BC+Dickerson&author=SN+Vaishnavi&publication_year=2015&hl=en']",26422359,https://doi.org/10.1016/j.neurobiolaging.2015.08.029, Wisse 2015 {published data only}  ,excluded,CD012216-bbs2-0041, Not having data for constructing a 2 x 2 table. The study was focused on characterising MCI participants separated into four groups according to their abnormal amyloid‐beta 42 levels and abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose PET and the conversion rate at 24 months.  
CD012216-bib-0052,"Xu L, Wu X, Li R, Chen K, Long Z, Zhang J, et al. ",Prediction of progressive mild cognitive impairment by multi‐modal neuroimaging biomarkers, Journal of Alzheimer's Disease ,2016,51,    ,['citation-journal']," Xu L, Wu X, Li R, Chen K, Long Z, Zhang J, et al. Prediction of progressive mild cognitive impairment by multi‐modal neuroimaging biomarkers.  Journal of Alzheimer's Disease 2016;51(4):1045‐56. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3233/JAD-151010', 'https://www.ncbi.nlm.nih.gov/pubmed/26923024', 'https://scholar.google.com/scholar_lookup?title=Prediction+of+progressive+mild+cognitive+impairment+by+multi‐modal+neuroimaging+biomarkers&author=L+Xu&author=X+Wu&author=R+Li&author=K+Chen&author=Z+Long&author=J+Zhang&publication_year=2016&hl=en']",26923024,https://doi.org/10.3233/JAD-151010, Xu 2016 {published data only}  ,excluded,CD012216-bbs2-0042," The study was focused on exploring the contribution of different neuroimaging modalities in their predictive power and characterised the sensitive biomarkers from each modality.  We did not include this study, as we preferred the Schreiber study to be included for the following reasons:     They used the same ADNI database and 70 of 110 MCI participants in Xu 2016 were also included in Schreiber 2015.    Schreiber had more participants: 401 MCI participants compared to 110 in the Xu study.    "
CD012216-bib-0063,"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. ",The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia ,2011,7,    ,['citation-journal']," Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.  Alzheimer's & Dementia 2011;7(3):270‐9.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2011.03.008', ""https://scholar.google.com/scholar_lookup?title=The+diagnosis+of+mild+cognitive+impairment+due+to+Alzheimer's+disease:+recommendations+from+the+National+Institute+on+Aging‐Alzheimer's+Association+workgroups+on+diagnostic+guidelines+for+Alzheimer's+disease+&author=MS+Albert&author=ST+DeKosky&author=D+Dickson&author=B+Dubois&author=HH+Feldman&author=NC+Fox&publication_year=2011&hl=en""]",,https://doi.org/10.1016/j.jalz.2011.03.008, Albert 2011 ,additional,CD012216-bbs2-0053,
CD012216-bib-0064,Alzheimer's Association. ,Changing the trajectory of Alzheimer's disease: a national imperative,,,,. http://www.alzheimersreadingroom.com/2010/05/changing‐trajectory‐of‐alzheimers.html (first accessed prior to 12 October 2017).   ,['citation-other'], Alzheimer's Association. Changing the trajectory of Alzheimer's disease: a national imperative. http://www.alzheimersreadingroom.com/2010/05/changing‐trajectory‐of‐alzheimers.html (first accessed prior to 12 October 2017).    ,[],,, Alzheimer's Association 2010 ,additional,CD012216-bbs2-0054,
CD012216-bib-0065,American Psychiatric Association. ,,Diagnostic and Statistical Manual of Mental Disorders,1987,,.   ,['citation-book']," American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.    ",[],,, APA 1987 ,additional,CD012216-bbs2-0055,
CD012216-bib-0066,American Psychiatric Association. ,,Diagnostic and Statistical Manual of Mental Disorders,1994,,.   ,['citation-book']," American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994.    ",[],,, APA 1994 ,additional,CD012216-bbs2-0056,
CD012216-bib-0067,"Archer HA, Smailagic N, John C, Holmes RB, Takwoingi Y, Coulthard EJ, et al. ",Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia, Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Archer HA, Smailagic N, John C, Holmes RB, Takwoingi Y, Coulthard EJ, et al. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia.  Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD010896.pub2]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010896.pub2', 'https://www.ncbi.nlm.nih.gov/pubmed/26102272', 'https://scholar.google.com/scholar_lookup?title=Regional+Cerebral+Blood+Flow+Single+Photon+Emission+Computed+Tomography+for+detection+of+Frontotemporal+dementia+in+people+with+suspected+dementia+&author=HA+Archer&author=N+Smailagic&author=C+John&author=RB+Holmes&author=Y+Takwoingi&author=EJ+Coulthard&publication_year=2015&hl=en']",26102272,https://doi.org/10.1002/14651858.CD010896.pub2, Archer 2015 ,additional,CD012216-bbs2-0057,
CD012216-bib-0068,"Arevalo‐Rodriguez I, Smailagic N, Figuls MRI, Ciapponi A, Sanchez‐Perez E, Giannakou A, et al. ",Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Arevalo‐Rodriguez I, Smailagic N, Figuls MRI, Ciapponi A, Sanchez‐Perez E, Giannakou A, et al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010783.pub2]    Google Scholar     ","[""https://scholar.google.com/scholar_lookup?title=Mini‐Mental+State+Examination+(MMSE)+for+the+detection+of+Alzheimer's+disease+and+other+dementias+in+people+with+mild+cognitive+impairment+(MCI)+&author=I+Arevalo‐Rodriguez&author=N+Smailagic&author=MRI+Figuls&author=A+Ciapponi&author=E+Sanchez‐Perez&author=A+Giannakou&publication_year=2015&hl=en""]",,, Arevalo‐Rodriguez 2015 ,additional,CD012216-bbs2-0058,
CD012216-bib-0069,"Bossuyt PM, Leeflang MM, editor(s). ","Chapter 6: Developing criteria for including studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 (updated September 2008). The Cochrane Collaboration, 2008",,,,. Available from srdta.cochrane.org.   ,['citation-other']," Bossuyt PM, Leeflang MM, editor(s). Chapter 6: Developing criteria for including studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 (updated September 2008). The Cochrane Collaboration, 2008. Available from srdta.cochrane.org.    ",[],,, Bossuyt 2008 ,additional,CD012216-bbs2-0059,
CD012216-bib-0070,"Boxer AL, Miller BL. ",Clinical features of frontotemporal dementia, Alzheimer Disease and Associated Disorders ,2005,19,    ,['citation-journal']," Boxer AL, Miller BL. Clinical features of frontotemporal dementia.  Alzheimer Disease and Associated Disorders 2005;19(Suppl 1):S3‐6.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/01.wad.0000183086.99691.91', 'https://www.ncbi.nlm.nih.gov/pubmed/16317256', 'https://scholar.google.com/scholar_lookup?title=Clinical+features+of+frontotemporal+dementia&author=AL+Boxer&author=BL+Miller&publication_year=2005&hl=en']",16317256,https://doi.org/10.1097/01.wad.0000183086.99691.91, Boxer 2005 ,additional,CD012216-bbs2-0060,
CD012216-bib-0071,"Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. ",Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups," Journal of Neurology, Neurosurgery, and Psychiatry ",1994,57,    ,['citation-journal']," Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.  Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(4):416‐8.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/8163988', 'https://scholar.google.com/scholar_lookup?title=Clinical+and+neuropathological+criteria+for+frontotemporal+dementia.+The+Lund+and+Manchester+Groups+&author=A+Brun&author=B+Englund&author=L+Gustafson&author=U+Passant&author=DMA+Mann&author=D+Neary&publication_year=1994&hl=en']",8163988,, Brun 1994 ,additional,CD012216-bbs2-0061,
CD012216-bib-0072,"Bruscoli M, Lovestone S. ",Is MCI really just early dementia? A systematic review of conversion studies, International Psychogeriatrics ,2004,16,    ,['citation-journal']," Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies.  International Psychogeriatrics 2004;16(2):129‐40.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1017/S1041610204000092', 'https://www.ncbi.nlm.nih.gov/pubmed/15318760', 'https://scholar.google.com/scholar_lookup?title=Is+MCI+really+just+early+dementia?+A+systematic+review+of+conversion+studies&author=M+Bruscoli&author=S+Lovestone&publication_year=2004&hl=en']",15318760,https://doi.org/10.1017/S1041610204000092, Bruscoli 2004 ,additional,CD012216-bbs2-0062,
CD012216-bib-0073,"Caroli A, Prestia A, Wade S, Chen K, Ayutyanont N, Landau SM, et al. ",Alzheimer disease biomarkers as outcome measures for clinical trials in MCI, Alzheimer Disease and Associated Disorders ,2015,29,    ,['citation-journal']," Caroli A, Prestia A, Wade S, Chen K, Ayutyanont N, Landau SM, et al. Alzheimer disease biomarkers as outcome measures for clinical trials in MCI.  Alzheimer Disease and Associated Disorders 2015;29(2):101‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/WAD.0000000000000071', 'https://www.ncbi.nlm.nih.gov/pubmed/25437302', 'https://scholar.google.com/scholar_lookup?title=Alzheimer+disease+biomarkers+as+outcome+measures+for+clinical+trials+in+MCI&author=A+Caroli&author=A+Prestia&author=S+Wade&author=K+Chen&author=N+Ayutyanont&author=SM+Landau&publication_year=2015&hl=en']",25437302,https://doi.org/10.1097/WAD.0000000000000071, Caroli 2015 ,additional,CD012216-bbs2-0063,
CD012216-bib-0074,"Chan CCH, Fage BA, Smailagic N, Gill SS, Herrmann N, Nikolaou V, et al. ",Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Chan CCH, Fage BA, Smailagic N, Gill SS, Herrmann N, Nikolaou V, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting.  Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011414]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011414', 'https://scholar.google.com/scholar_lookup?title=Mini‐Cog+for+the+diagnosis+of+Alzheimer’s+disease+dementia+and+other+dementias+within+a+secondary+care+setting+&author=CCH+Chan&author=BA+Fage&author=N+Smailagic&author=SS+Gill&author=N+Herrmann&author=V+Nikolaou&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD011414, Chan 2014 ,additional,CD012216-bbs2-0064,
CD012216-bib-0075,"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. ",Preclinical properties of 18F‐AV‐45: a PET agent for Abeta plaques in the brain, Journal of Nuclear Medicine ,2009,50,    ,['citation-journal']," Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F‐AV‐45: a PET agent for Abeta plaques in the brain.  Journal of Nuclear Medicine 2009;50(11):1887‐94.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.2967/jnumed.109.065284', 'https://www.ncbi.nlm.nih.gov/pubmed/19837759', 'https://scholar.google.com/scholar_lookup?title=Preclinical+properties+of+18F‐AV‐45:+a+PET+agent+for+Abeta+plaques+in+the+brain&author=SR+Choi&author=G+Golding&author=Z+Zhuang&author=W+Zhang&author=N+Lim&author=F+Hefti&publication_year=2009&hl=en']",19837759,https://doi.org/10.2967/jnumed.109.065284, Choi 2009 ,additional,CD012216-bbs2-0065,
CD012216-bib-0076,"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. ",Use of florbetapir‐PET for imaging beta‐amyloid pathology, JAMA ,2011,305,    ,['citation-journal']," Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir‐PET for imaging beta‐amyloid pathology.  JAMA 2011;305(3):275‐83.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2010.2008', 'https://www.ncbi.nlm.nih.gov/pubmed/21245183', 'https://scholar.google.com/scholar_lookup?title=Use+of+florbetapir‐PET+for+imaging+beta‐amyloid+pathology&author=CM+Clark&author=JA+Schneider&author=BJ+Bedell&author=TG+Beach&author=WB+Bilker&author=MA+Mintun&publication_year=2011&hl=en']",21245183,https://doi.org/10.1001/jama.2010.2008, Clark 2011 ,additional,CD012216-bbs2-0066,
CD012216-bib-0077,"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. ",Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid‐β plaques: a prospective cohort study, Lancet Neurology ,2012,11,    ,['citation-journal']," Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid‐β plaques: a prospective cohort study.  Lancet Neurology 2012;11(8):669‐78.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1474-4422(12)70142-4', 'https://www.ncbi.nlm.nih.gov/pubmed/22749065', 'https://scholar.google.com/scholar_lookup?title=Cerebral+PET+with+florbetapir+compared+with+neuropathology+at+autopsy+for+detection+of+neuritic+amyloid‐β+plaques:+a+prospective+cohort+study+&author=CM+Clark&author=MJ+Pontecorvo&author=TG+Beach&author=BJ+Bedell&author=RE+Coleman&author=PM+Doraiswamy&publication_year=2012&hl=en']",22749065,https://doi.org/10.1016/S1474-4422(12)70142-4, Clark 2012 ,additional,CD012216-bbs2-0067,
CD012216-bib-0078,Centers for Medicare & Medicaid Services. ,Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG‐00431N),,,,. www.cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NCAId=265 (accessed 08/10/2015).   ,['citation-other'], Centers for Medicare & Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG‐00431N). www.cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NCAId=265 (accessed 08/10/2015).    ,[],,, CMS 2013 ,additional,CD012216-bbs2-0068,
CD012216-bib-0079,"Cordella CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. ",Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting, Alzheimer's & Dementia ,2013,9,    ,['citation-journal']," Cordella CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting.  Alzheimer's & Dementia 2013;9(2):141‐50.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2012.09.011', ""https://scholar.google.com/scholar_lookup?title=Alzheimer's+Association+recommendations+for+operationalizing+the+detection+of+cognitive+impairment+during+the+Medicare+Annual+Wellness+Visit+in+a+primary+care+setting+&author=CB+Cordella&author=S+Borson&author=M+Boustani&author=J+Chodosh&author=D+Reuben&author=J+Verghese&publication_year=2013&hl=en""]",,https://doi.org/10.1016/j.jalz.2012.09.011, Cordella 2013 ,additional,CD012216-bbs2-0069,
CD012216-bib-0080,"Creavin S, Wisniewski S, Noel‐Storr A, Trevelyan C, Hampton T, Rayment D, et al. ",Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations, Cochrane Database of Systematic Reviews ,2016,,    ,['citation-journal']," Creavin S, Wisniewski S, Noel‐Storr A, Trevelyan C, Hampton T, Rayment D, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations.  Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD011145.pub2]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011145.pub2', 'https://www.ncbi.nlm.nih.gov/pubmed/26760674', 'https://scholar.google.com/scholar_lookup?title=Mini‐Mental+State+Examination+(MMSE)+for+the+detection+of+dementia+in+clinically+unevaluated+people+aged+65+and+over+in+community+and+primary+care+populations+&author=S+Creavin&author=S+Wisniewski&author=A+Noel‐Storr&author=C+Trevelyan&author=T+Hampton&author=D+Rayment&publication_year=2016&hl=en']",26760674,https://doi.org/10.1002/14651858.CD011145.pub2, Creavin 2016 ,additional,CD012216-bbs2-0070,
CD012216-bib-0081,"Davis DHJ, Creavin ST, Noel‐Storr A, Quinn TJ, Smailagic N, Hyde C, et al. ",Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies, Cochrane Database of Systematic Reviews ,2013,,    ,['citation-journal']," Davis DHJ, Creavin ST, Noel‐Storr A, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies.  Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010460]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010460', 'https://scholar.google.com/scholar_lookup?title=Neuropsychological+tests+for+the+diagnosis+of+Alzheimer’s+disease+dementia+and+other+dementias:+a+generic+protocol+for+cross‐sectional+and+delayed‐verification+studies+&author=DHJ+Davis&author=ST+Creavin&author=A+Noel‐Storr&author=TJ+Quinn&author=N+Smailagic&author=C+Hyde&publication_year=2013&hl=en']",,https://doi.org/10.1002/14651858.CD010460, Davis 2013 ,additional,CD012216-bbs2-0071,
CD012216-bib-0082,"Davis DHJ, Creavin ST, Yip JLY, Noel‐Storr AH, Brayne C, Cullum S. ",Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias, Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Davis DHJ, Creavin ST, Yip JLY, Noel‐Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias.  Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010775.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010775.pub2', 'https://scholar.google.com/scholar_lookup?title=Montreal+Cognitive+Assessment+for+the+diagnosis+of+Alzheimer’s+disease+and+other+dementias&author=DHJ+Davis&author=ST+Creavin&author=JLY+Yip&author=AH+Noel‐Storr&author=C+Brayne&author=S+Cullum&publication_year=2015&hl=en']",,https://doi.org/10.1002/14651858.CD010775.pub2, Davis 2015 ,additional,CD012216-bbs2-0072,
CD012216-bib-0083,De la Torre JC. ,"Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics", Lancet Neurology ,2004,3,    ,['citation-journal']," De la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics.  Lancet Neurology 2004;3(3):184‐90.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1474-4422(04)00683-0', 'https://www.ncbi.nlm.nih.gov/pubmed/14980533', ""https://scholar.google.com/scholar_lookup?title=Is+Alzheimer's+disease+a+neurodegenerative+or+a+vascular+disorder?+Data,+dogma,+and+dialectics+&author=JC+Torre&publication_year=2004&hl=en""]",14980533,https://doi.org/10.1016/S1474-4422(04)00683-0, De la Torre 2004 ,additional,CD012216-bbs2-0073,
CD012216-bib-0084,"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. ",Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria, Lancet Neurology ,2014,13,    ,['citation-journal']," Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria.  Lancet Neurology 2014;13(6):614‐29.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1474-4422(14)70090-0', 'https://www.ncbi.nlm.nih.gov/pubmed/24849862', ""https://scholar.google.com/scholar_lookup?title=Advancing+research+diagnostic+criteria+for+Alzheimer's+disease:+the+IWG‐2+criteria&author=B+Dubois&author=HH+Feldman&author=C+Jacova&author=H+Hampel&author=JL+Molinuevo&author=K+Blennow&publication_year=2014&hl=en""]",24849862,https://doi.org/10.1016/S1474-4422(14)70090-0, Dubois 2014 ,additional,CD012216-bbs2-0074,
CD012216-bib-0085,"Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. ",APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting.  Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010948]    Google Scholar     ","[""https://scholar.google.com/scholar_lookup?title=APOE‐ϵ4+allele+for+the+diagnosis+of+Alzheimer's+and+other+dementia+disorders+in+people+with+mild+cognitive+impairment+in+a+community+setting+&author=LS+Elias‐Sonnenschein&author=W+Viechtbauer&author=I+Ramakers&author=O+Ukoumunne&author=FRJ+Verhey&author=PJ+Visser&publication_year=2014&hl=en""]",,, Elias‐Sonnenschein 2014a ,additional,CD012216-bbs2-0075,
CD012216-bib-0086,"Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. ",APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting.  Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010949]    Google Scholar     ","[""https://scholar.google.com/scholar_lookup?title=APOE‐ϵ4+allele+for+the+diagnosis+of+Alzheimer's+and+other+dementia+disorders+in+people+with+mild+cognitive+impairment+in+a+primary+care+setting+&author=LS+Elias‐Sonnenschein&author=W+Viechtbauer&author=I+Ramakers&author=O+Ukoumunne&author=FRJ+Verhey&author=PJ+Visser&publication_year=2014&hl=en""]",,, Elias‐Sonnenschein 2014b ,additional,CD012216-bbs2-0076,
CD012216-bib-0087,"Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. ",APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting.  Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010950]    Google Scholar     ","[""https://scholar.google.com/scholar_lookup?title=APOE‐ϵ4+allele+for+the+diagnosis+of+Alzheimer's+and+other+dementia+disorders+in+people+with+mild+cognitive+impairment+in+a+secondary+care+setting+&author=LS+Elias‐Sonnenschein&author=W+Viechtbauer&author=I+Ramakers&author=O+Ukoumunne&author=FRJ+Verhey&author=PJ+Visser&publication_year=2014&hl=en""]",,, Elias‐Sonnenschein 2014c ,additional,CD012216-bbs2-0077,
CD012216-bib-0088,European Medicines Agency. ,Assessment report. Amyvid. International non‐proprietary name: florbetapir (18F) Procedure No. EMEA/H/C/002422,,,,. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002422/WC500137634.pdf (accessed 8th April 2015).   ,['citation-other'], European Medicines Agency. Assessment report. Amyvid. International non‐proprietary name: florbetapir (18F) Procedure No. EMEA/H/C/002422. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002422/WC500137634.pdf (accessed 8th April 2015).    ,[],,, EMA 2013 ,additional,CD012216-bbs2-0078,
CD012216-bib-0089,"Espinosa A, Alegret M, Valero S, Vinyes‐Junque G, Hernandez I, Mauleon A, et al. ",A longitudinal follow‐up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved, Journal of Alzheimer’s Disease ,2013,34,    ,['citation-journal']," Espinosa A, Alegret M, Valero S, Vinyes‐Junque G, Hernandez I, Mauleon A, et al. A longitudinal follow‐up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved.  Journal of Alzheimer’s Disease 2013;34(3):769‐80.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3233/JAD-122002', 'https://www.ncbi.nlm.nih.gov/pubmed/23271318', 'https://scholar.google.com/scholar_lookup?title=A+longitudinal+follow‐up+of+550+mild+cognitive+impairment+patients:+evidence+for+large+conversion+to+dementia+rates+and+detection+of+major+risk+factors+involved+&author=A+Espinosa&author=M+Alegret&author=S+Valero&author=G+Vinyes‐Junque&author=I+Hernandez&author=A+Mauleon&publication_year=2013&hl=en']",23271318,https://doi.org/10.3233/JAD-122002, Espinosa 2013 ,additional,CD012216-bbs2-0079,
CD012216-bib-0090,"Fage BA, Chan CCH, Gill SS, Noel‐Storr AH, Herrmann N, Smailagic N, et al. ",Mini‐Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting, Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Fage BA, Chan CCH, Gill SS, Noel‐Storr AH, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting.  Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD010860.pub2]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010860.pub2', 'https://www.ncbi.nlm.nih.gov/pubmed/25922857', ""https://scholar.google.com/scholar_lookup?title=Mini‐Cog+for+the+diagnosis+of+Alzheimer's+disease+dementia+and+other+dementias+within+a+community+setting+&author=BA+Fage&author=CCH+Chan&author=SS+Gill&author=AH+Noel‐Storr&author=N+Herrmann&author=N+Smailagic&publication_year=2015&hl=en""]",25922857,https://doi.org/10.1002/14651858.CD010860.pub2, Fage 2015 ,additional,CD012216-bbs2-0080,
CD012216-bib-0091,"Food, Drug Administration. ",Amyvid,,,,. www.accessdata.fda.gov/drugsatfda_docs/label/2013/202008s020lbl.pdf (accessed 8 April 2015).   ,['citation-other']," Food, Drug Administration. Amyvid. www.accessdata.fda.gov/drugsatfda_docs/label/2013/202008s020lbl.pdf (accessed 8 April 2015).    ",[],,, FDA 2013 ,additional,CD012216-bbs2-0081,
CD012216-bib-0092,"Filippini G, Casazza G, Bellatorre AG, Lista C, Duca P, Beecher D, et al. ",The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2012,,    ,['citation-journal']," Filippini G, Casazza G, Bellatorre AG, Lista C, Duca P, Beecher D, et al. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009628]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD009628', 'https://scholar.google.com/scholar_lookup?title=The+role+of+MRI+in+the+early+diagnosis+of+Alzheimer’s+disease+or+other+dementias+in+persons+with+mild+cognitive+impairment+(MCI)+&author=G+Filippini&author=G+Casazza&author=AG+Bellatorre&author=C+Lista&author=P+Duca&author=D+Beecher&publication_year=2012&hl=en']",,https://doi.org/10.1002/14651858.CD009628, Filippini 2012 ,additional,CD012216-bbs2-0082,
CD012216-bib-0093,"Garcia‐Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. ",Cerebrovascular lesions induce transient β‐amyloid deposition, Brain ,2011,134,    ,['citation-journal']," Garcia‐Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. Cerebrovascular lesions induce transient β‐amyloid deposition.  Brain 2011;134(12):3697‐707.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/brain/awr300', 'https://www.ncbi.nlm.nih.gov/pubmed/22120142', 'https://scholar.google.com/scholar_lookup?title=Cerebrovascular+lesions+induce+transient+β‐amyloid+deposition&author=M+Garcia‐Alloza&author=J+Gregory&author=KV+Kuchibhotla&author=S+Fine&author=Y+Wei&author=C+Ayata&publication_year=2011&hl=en']",22120142,https://doi.org/10.1093/brain/awr300, Garcia‐Alloza 2011 ,additional,CD012216-bbs2-0083,
CD012216-bib-0094,"Gelber RP, Launer LJ, White LR. ",The Honolulu‐Asia Aging Study: epidemiologic and neuropathologic research on cognitive impairment, Current Alzheimer Research ,2012,9,    ,['citation-journal']," Gelber RP, Launer LJ, White LR. The Honolulu‐Asia Aging Study: epidemiologic and neuropathologic research on cognitive impairment.  Current Alzheimer Research 2012;9(6):664‐72.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.2174/156720512801322618', 'https://www.ncbi.nlm.nih.gov/pubmed/22471866', 'https://scholar.google.com/scholar_lookup?title=The+Honolulu‐Asia+Aging+Study:+epidemiologic+and+neuropathologic+research+on+cognitive+impairment+&author=RP+Gelber&author=LJ+Launer&author=LR+White&publication_year=2012&hl=en']",22471866,https://doi.org/10.2174/156720512801322618, Gelber 2012 ,additional,CD012216-bbs2-0084,
CD012216-bib-0095,"Geslani DM, Tierney MC, Herrmann N, Szalai JP. ",Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease, Dementia and Geriatric Cognitive Disorders ,2005,19,    ,['citation-journal']," Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease.  Dementia and Geriatric Cognitive Disorders 2005;19(5‐6):383‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1159/000084709', 'https://www.ncbi.nlm.nih.gov/pubmed/15802914', 'https://scholar.google.com/scholar_lookup?title=Mild+cognitive+impairment:+an+operational+definition+and+its+conversion+rate+to+Alzheimer’s+disease+&author=DM+Geslani&author=MC+Tierney&author=N+Herrmann&author=JP+Szalai&publication_year=2005&hl=en']",15802914,https://doi.org/10.1159/000084709, Geslani 2005 ,additional,CD012216-bbs2-0085,
CD012216-bib-0096,"Goedert M, Spillantini MG. ",A century of Alzheimer's disease, Science ,2006,314,    ,['citation-journal']," Goedert M, Spillantini MG. A century of Alzheimer's disease.  Science 2006;314(5800):777‐81.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1126/science.1132814', 'https://www.ncbi.nlm.nih.gov/pubmed/17082447', ""https://scholar.google.com/scholar_lookup?title=A+century+of+Alzheimer's+disease&author=M+Goedert&author=MG+Spillantini&publication_year=2006&hl=en""]",17082447,https://doi.org/10.1126/science.1132814, Goedert 2006 ,additional,CD012216-bbs2-0086,
CD012216-bib-0097,"Gurol ME, Becker JA, Fotiadis P, Riley G, Schwab K, Johnson KA, et al. ",Florbetapir‐PET to diagnose cerebral amyloid angiopathy: a prospective study, Neurology ,2016,87,    ,['citation-journal']," Gurol ME, Becker JA, Fotiadis P, Riley G, Schwab K, Johnson KA, et al. Florbetapir‐PET to diagnose cerebral amyloid angiopathy: a prospective study.  Neurology 2016;87(19):2043‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.0000000000003197', 'https://www.ncbi.nlm.nih.gov/pubmed/27605173', 'https://scholar.google.com/scholar_lookup?title=Florbetapir‐PET+to+diagnose+cerebral+amyloid+angiopathy:+a+prospective+study&author=ME+Gurol&author=JA+Becker&author=P+Fotiadis&author=G+Riley&author=K+Schwab&author=KA+Johnson&publication_year=2016&hl=en']",27605173,https://doi.org/10.1212/WNL.0000000000003197, Gurol 2016 ,additional,CD012216-bbs2-0087,
CD012216-bib-0098,"Hampel H, Lista S, Khachaturian Z. ",Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot, Alzheimer's & Dementia ,2012,8,    ,['citation-journal']," Hampel H, Lista S, Khachaturian Z. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot.  Alzheimer's & Dementia 2012;8(4):312‐36.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2012.05.2116', 'https://scholar.google.com/scholar_lookup?title=Development+of+biomarkers+to+chart+all+Alzheimer’s+disease+stages:+the+royal+road+to+cutting+the+therapeutic+Gordian+Knot+&author=H+Hampel&author=S+Lista&author=Z+Khachaturian&publication_year=2012&hl=en']",,https://doi.org/10.1016/j.jalz.2012.05.2116, Hampel 2012 ,additional,CD012216-bbs2-0088,
CD012216-bib-0099,"Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. ",Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting.  Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010771.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010771.pub2', 'https://scholar.google.com/scholar_lookup?title=Informant+Questionnaire+on+Cognitive+Decline+in+the+Elderly+(IQCODE)+for+the+diagnosis+of+dementia+within+a+general+practice+(primary+care)+setting+&author=JK+Harrison&author=P+Fearon&author=AH+Noel‐Storr&author=R+McShane&author=DJ+Stott&author=TJ+Quinn&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD010771.pub2, Harrison 2014 ,additional,CD012216-bbs2-0089,
CD012216-bib-0100,"Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. ",Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting, Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting.  Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010772.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010772.pub2', 'https://scholar.google.com/scholar_lookup?title=Informant+Questionnaire+on+Cognitive+Decline+in+the+Elderly+(IQCODE)+for+the+diagnosis+of+dementia+within+a+secondary+care+setting+&author=JK+Harrison&author=P+Fearon&author=AH+Noel‐Storr&author=R+McShane&author=DJ+Stott&author=TJ+Quinn&publication_year=2015&hl=en']",,https://doi.org/10.1002/14651858.CD010772.pub2, Harrison 2015 ,additional,CD012216-bbs2-0090,
CD012216-bib-0101,"Hendry K, Lees RA, McShane R, Noel‐Storr AH, Stott DJ, Quinn TJ. ",AD‐8 for diagnosis of dementia across a variety of healthcare settings, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Hendry K, Lees RA, McShane R, Noel‐Storr AH, Stott DJ, Quinn TJ. AD‐8 for diagnosis of dementia across a variety of healthcare settings.  Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011121]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011121', 'https://scholar.google.com/scholar_lookup?title=AD‐8+for+diagnosis+of+dementia+across+a+variety+of+healthcare+settings&author=K+Hendry&author=RA+Lees&author=R+McShane&author=AH+Noel‐Storr&author=DJ+Stott&author=TJ+Quinn&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD011121, Hendry 2014 ,additional,CD012216-bbs2-0091,
CD012216-bib-0102,Herscovitch P. ,Regulatory approval and insurance reimbursement: the final steps in clinical translation of amyloid brain imaging, Clinical and Translational Imaging ,2015,3,    ,['citation-journal'], Herscovitch P. Regulatory approval and insurance reimbursement: the final steps in clinical translation of amyloid brain imaging.  Clinical and Translational Imaging 2015;3:75‐7.    Link to article     Google Scholar     ,"['https://doi.org/10.1007/s40336-015-0101-7', 'https://scholar.google.com/scholar_lookup?title=Regulatory+approval+and+insurance+reimbursement:+the+final+steps+in+clinical+translation+of+amyloid+brain+imaging+&author=P+Herscovitch&publication_year=2015&hl=en']",,https://doi.org/10.1007/s40336-015-0101-7, Herscovitch 2015 ,additional,CD012216-bbs2-0092,
CD012216-bib-0103,"Hayden EY, Teplow DB. ",Amyloid β‐protein oligomers and Alzheimer’s disease, Alzheimer's Research & Therapy ,2013,5,    ,['citation-journal']," Hayden EY, Teplow DB. Amyloid β‐protein oligomers and Alzheimer’s disease.  Alzheimer's Research & Therapy 2013;5(5):1‐11.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/alzrt226', 'https://www.ncbi.nlm.nih.gov/pubmed/23302773', 'https://scholar.google.com/scholar_lookup?title=Amyloid+β‐protein+oligomers+and+Alzheimer’s+disease&author=EY+Hayden&author=DB+Teplow&publication_year=2013&hl=en']",23302773,https://doi.org/10.1186/alzrt226, Heyden 2013 ,additional,CD012216-bbs2-0093,
CD012216-bib-0104,"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. ",National Institute on Aging‐Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease, Alzheimer's & Dementia ,2012,8,    ,['citation-journal']," Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging‐Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.  Alzheimer's & Dementia 2012;8(1):1‐13.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2011.10.007', ""https://scholar.google.com/scholar_lookup?title=National+Institute+on+Aging‐Alzheimer's+Association+guidelines+for+the+neuropathologic+assessment+of+Alzheimer's+disease+&author=BT+Hyman&author=CH+Phelps&author=TG+Beach&author=EH+Bigio&author=NJ+Cairns&author=MC+Carrillo&publication_year=2012&hl=en""]",,https://doi.org/10.1016/j.jalz.2011.10.007, Hyman 2012 ,additional,CD012216-bbs2-0094,
CD012216-bib-0105,World Health Organization. ,International Statistical Classification of Diseases and Related Health Problems (ICD‐10 Version: 2010),,,,. apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015).   ,['citation-other'], World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD‐10 Version: 2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015).    ,[],,, ICD‐10 ,additional,CD012216-bbs2-0095,
CD012216-bib-0106,"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. ",Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, Lancet Neurology ,2013,12,    ,['citation-journal']," Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.  Lancet Neurology 2013;12(2):207‐16.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1474-4422(12)70291-0', 'https://www.ncbi.nlm.nih.gov/pubmed/23332364', ""https://scholar.google.com/scholar_lookup?title=Tracking+pathophysiological+processes+in+Alzheimer's+disease:+an+updated+hypothetical+model+of+dynamic+biomarkers+&author=CR+Jack&author=DS+Knopman&author=WJ+Jagust&author=RC+Petersen&author=MW+Weiner&author=PS+Aisen&publication_year=2013&hl=en""]",23332364,https://doi.org/10.1016/S1474-4422(12)70291-0, Jack 2013 ,additional,CD012216-bbs2-0096,
CD012216-bib-0107,Jellinger K. ,Clinicopathological analysis of dementia disorders in the elderly ‐ update, Journal of Alzheimer's Disease ,2006,9,    ,['citation-journal'], Jellinger K. Clinicopathological analysis of dementia disorders in the elderly ‐ update.  Journal of Alzheimer's Disease 2006;9(Supplement 3):61‐70.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.3233/JAD-2006-9S308', 'https://www.ncbi.nlm.nih.gov/pubmed/16914845', 'https://scholar.google.com/scholar_lookup?title=Clinicopathological+analysis+of+dementia+disorders+in+the+elderly+‐+update&author=K+Jellinger&publication_year=2006&hl=en']",16914845,https://doi.org/10.3233/JAD-2006-9S308, Jellinger 2006 ,additional,CD012216-bbs2-0097,
CD012216-bib-0108,"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. ","Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association", Journal of Nuclear Medicine ,2013,54,    ,['citation-journal']," Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.  Journal of Nuclear Medicine 2013;54(3):476‐90.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.2967/jnumed.113.120618', 'https://www.ncbi.nlm.nih.gov/pubmed/23359661', ""https://scholar.google.com/scholar_lookup?title=Appropriate+use+criteria+for+amyloid+PET:+a+report+of+the+Amyloid+Imaging+Task+Force,+the+Society+of+Nuclear+Medicine+and+Molecular+Imaging,+and+the+Alzheimer's+Association+&author=KA+Johnson&author=S+Minoshima&author=NI+Bohnen&author=KJ+Donohoe&author=NL+Foster&author=P+Herscovitch&publication_year=2013&hl=en""]",23359661,https://doi.org/10.2967/jnumed.113.120618, Johnson 2013 ,additional,CD012216-bbs2-0098,
CD012216-bib-0109,"Knottnerus JA, Van Weel C, Muris JW. ",Evaluation of diagnostic procedures, BMJ ,2002,324,    ,['citation-journal']," Knottnerus JA, Van Weel C, Muris JW. Evaluation of diagnostic procedures.  BMJ 2002;324(7335):477‐80.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.324.7335.477', 'https://www.ncbi.nlm.nih.gov/pubmed/11859054', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+diagnostic+procedures&author=JA+Knottnerus&author=C+Weel&author=JW+Muris&publication_year=2002&hl=en']",11859054,https://doi.org/10.1136/bmj.324.7335.477, Knottnerus 2002 ,additional,CD012216-bbs2-0099,
CD012216-bib-0110,"Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, et al. ",18F‐Florbetapir PET in patients with frontotemporal dementia and Alzheimer disease, Journal of Nuclear Medicine ,2015,56,    ,['citation-journal']," Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, et al. 18F‐Florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.  Journal of Nuclear Medicine 2015;56(3):386‐91.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.2967/jnumed.114.147454', 'https://www.ncbi.nlm.nih.gov/pubmed/25655625', 'https://scholar.google.com/scholar_lookup?title=18F‐Florbetapir+PET+in+patients+with+frontotemporal+dementia+and+Alzheimer+disease&author=C+Kobylecki&author=T+Langheinrich&author=R+Hinz&author=ER+Vardy&author=G+Brown&author=ME+Martino&publication_year=2015&hl=en']",25655625,https://doi.org/10.2967/jnumed.114.147454, Kobylecki 2015 ,additional,CD012216-bbs2-0100,
CD012216-bib-0111,"Kokkinou M, Smailagic N, Noel‐Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al. ",Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Kokkinou M, Smailagic N, Noel‐Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.  Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010945]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010945', ""https://scholar.google.com/scholar_lookup?title=Plasma+and+Cerebrospinal+fluid+(CSF)+Abeta42+for+the+differential+diagnosis+of+Alzheimer's+disease+dementia+in+participants+diagnosed+with+any+dementia+subtype+in+a+specialist+care+setting+&author=M+Kokkinou&author=N+Smailagic&author=AH+Noel‐Storr&author=C+Hyde&author=O+Ukoumunne&author=RE+Worrall&publication_year=2014&hl=en""]",,https://doi.org/10.1002/14651858.CD010945, Kokkinou 2014 ,additional,CD012216-bbs2-0101,
CD012216-bib-0112,"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. ","Amyloid deposition, hypometabolism, and longitudinal cognitive decline", Annals of Neurology ,2012,72,    ,['citation-journal']," Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.  Annals of Neurology 2012;72(4):578‐86.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/ana.23650', 'https://www.ncbi.nlm.nih.gov/pubmed/23109153', 'https://scholar.google.com/scholar_lookup?title=Amyloid+deposition,+hypometabolism,+and+longitudinal+cognitive+decline&author=SM+Landau&author=MA+Mintun&author=AD+Joshi&author=RA+Koeppe&author=RC+Petersen&author=PS+Aisen&publication_year=2012&hl=en']",23109153,https://doi.org/10.1002/ana.23650, Landau 2012 ,additional,CD012216-bbs2-0102,
CD012216-bib-0113,"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. ",Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid, Annal of Neurology ,2013,74,    ,['citation-journal']," Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid.  Annal of Neurology 2013;74(6):826‐36.    Link to article     Google Scholar     ","['https://doi.org/10.1002/ana.23908', 'https://scholar.google.com/scholar_lookup?title=Comparing+positron+emission+tomography+imaging+and+cerebrospinal+fluid+measurements+of+β‐amyloid+&author=SM+Landau&author=M+Lu&author=AD+Joshi&author=M+Pontecorvo&author=MA+Mintun&author=JQ+Trojanowski&publication_year=2013&hl=en']",,https://doi.org/10.1002/ana.23908, Landau 2013 ,additional,CD012216-bbs2-0103,
CD012216-bib-0114,"Lees RA, Stott DJ, McShane R, Noel‐Storr AH, Quinn TJ. ",Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Lees RA, Stott DJ, McShane R, Noel‐Storr AH, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings.  Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD011333]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011333', 'https://www.ncbi.nlm.nih.gov/pubmed/25517473', 'https://scholar.google.com/scholar_lookup?title=Informant+Questionnaire+on+Cognitive+Decline+in+the+Elderly+(IQCODE)+for+the+early+diagnosis+of+dementia+across+a+variety+of+healthcare+settings+&author=RA+Lees&author=DJ+Stott&author=R+McShane&author=AH+Noel‐Storr&author=TJ+Quinn&publication_year=2014&hl=en']",25517473,https://doi.org/10.1002/14651858.CD011333, Lees 2014 ,additional,CD012216-bbs2-0104,
CD012216-bib-0115,"Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. ","Whole‐body biodistribution and brain PET imaging with [18F]AV‐45, a novel amyloid imaging agent ‐ a pilot study", Nuclear Medicine and Biology ,2010,37,    ,['citation-journal']," Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole‐body biodistribution and brain PET imaging with [18F]AV‐45, a novel amyloid imaging agent ‐ a pilot study.  Nuclear Medicine and Biology 2010;37(4):497‐508.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.nucmedbio.2010.02.003', 'https://www.ncbi.nlm.nih.gov/pubmed/20447562', 'https://scholar.google.com/scholar_lookup?title=Whole‐body+biodistribution+and+brain+PET+imaging+with+[18F]AV‐45,+a+novel+amyloid+imaging+agent+‐+a+pilot+study+&author=KJ+Lin&author=WC+Hsu&author=IT+Hsiao&author=SP+Wey&author=LW+Jin&author=D+Skovronsky&publication_year=2010&hl=en']",20447562,https://doi.org/10.1016/j.nucmedbio.2010.02.003, Lin 2010 ,additional,CD012216-bbs2-0105,
CD012216-bib-0116,"Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. ",Industry sponsorship and research outcome, Cochrane Database of Systematic Reviews ,2017,,    ,['citation-journal']," Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome.  Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub2]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.MR000033.pub3', 'https://www.ncbi.nlm.nih.gov/pubmed/28207928', 'https://scholar.google.com/scholar_lookup?title=Industry+sponsorship+and+research+outcome&author=A+Lundh&author=S+Sismondo&author=J+Lexchin&author=OA+Busuioc&author=L+Bero&publication_year=2017&hl=en']",28207928,https://doi.org/10.1002/14651858.MR000033.pub3, Lundh 2017 ,additional,CD012216-bbs2-0106,
CD012216-bib-0117,"Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, et al. ",Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow‐up: a meta‐analysis, Medicine ,2014,93,    ,['citation-journal']," Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow‐up: a meta‐analysis.  Medicine 2014;93(27):1‐12.    Link to article     Google Scholar     ","['https://doi.org/10.1097/MD.0000000000000150', 'https://scholar.google.com/scholar_lookup?title=Predictive+accuracy+of+amyloid+imaging+for+progression+from+mild+cognitive+impairment+to+Alzheimer+disease+with+different+lengths+of+follow‐up:+a+meta‐analysis+&author=Y+Ma&author=S+Zhang&author=J+Li&author=DM+Zheng&author=Y+Guo&author=J+Feng&publication_year=2014&hl=en']",,https://doi.org/10.1097/MD.0000000000000150, Ma 2014 ,additional,CD012216-bbs2-0107,
CD012216-bib-0118,"Martínez G, Flicker L, Vernooij RWM, Fuentes Padilla P, Zamora J, Figuls MRI, et al. ",18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2016,,    ,['citation-journal']," Martínez G, Flicker L, Vernooij RWM, Fuentes Padilla P, Zamora J, Figuls MRI, et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012216]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD012216', 'https://www.ncbi.nlm.nih.gov/pubmed/27959472', 'https://scholar.google.com/scholar_lookup?title=18F+PET+ligands+for+the+early+diagnosis+of+Alzheimer’s+disease+dementia+and+other+dementias+in+people+with+mild+cognitive+impairment+(MCI)+&author=G+Martínez&author=L+Flicker&author=RWM+Vernooij&author=P+FuentesPadilla&author=J+Zamora&author=MRI+Figuls&publication_year=2016&hl=en']",27959472,https://doi.org/10.1002/14651858.CD012216, Martínez 2016 ,additional,CD012216-bbs2-0108,
CD012216-bib-0119,"Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Ageing Study. ",Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?, Journal of the American Geriatrics Society ,2008,56,    ,['citation-journal']," Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?.  Journal of the American Geriatrics Society 2008;56(8):1424‐33.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1532-5415.2008.01820.x', 'https://www.ncbi.nlm.nih.gov/pubmed/18662209', 'https://scholar.google.com/scholar_lookup?title=Two‐year+progression+from+mild+cognitive+impairment+to+dementia:+to+what+extent+do+different+definitions+agree?+&author=FE+Matthews&author=BC+Stephan&author=IG+McKeith&author=J+Bond&author=C+Brayne&publication_year=2008&hl=en']",18662209,https://doi.org/10.1111/j.1532-5415.2008.01820.x, Matthews 2008 ,additional,CD012216-bbs2-0109,
CD012216-bib-0120,"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. ",CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA ,2009,302,    ,['citation-journal']," Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.  JAMA 2009;302(4):385‐93.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2009.1064', 'https://www.ncbi.nlm.nih.gov/pubmed/19622817', 'https://scholar.google.com/scholar_lookup?title=CSF+biomarkers+and+incipient+Alzheimer+disease+in+patients+with+mild+cognitive+impairment&author=N+Mattsson&author=H+Zetterberg&author=O+Hansson&author=N+Andreasen&author=L+Parnetti&author=M+Jonsson&publication_year=2009&hl=en']",19622817,https://doi.org/10.1001/jama.2009.1064, Mattsson 2009 ,additional,CD012216-bbs2-0110,
CD012216-bib-0121,"McCleery J, Morgan S, Bradley KM, Noel‐Storr AH, Ansorge O, Hyde C. ",Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies, Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," McCleery J, Morgan S, Bradley KM, Noel‐Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.  Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010633.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010633.pub2', 'https://scholar.google.com/scholar_lookup?title=Dopamine+transporter+imaging+for+the+diagnosis+of+dementia+with+Lewy+bodies&author=J+McCleery&author=S+Morgan&author=KM+Bradley&author=AH+Noel‐Storr&author=O+Ansorge&author=C+Hyde&publication_year=2015&hl=en']",,https://doi.org/10.1002/14651858.CD010633.pub2, McCleery 2015 ,additional,CD012216-bbs2-0111,
CD012216-bib-0122,"McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. ",Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop, Neurology ,1996,47,    ,['citation-journal']," McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.  Neurology 1996;47(5):1113‐24.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.47.5.1113', 'https://www.ncbi.nlm.nih.gov/pubmed/8909416', 'https://scholar.google.com/scholar_lookup?title=Consensus+guidelines+for+the+clinical+and+pathologic+diagnosis+of+dementia+with+Lewy+bodies+(DLB):+report+of+the+consortium+on+DLB+international+workshop+&author=IG+McKeith&author=D+Galasko&author=K+Kosaka&author=EK+Perry&author=DW+Dickson&author=LA+Hansen&publication_year=1996&hl=en']",8909416,https://doi.org/10.1212/WNL.47.5.1113, McKeith 1996 ,additional,CD012216-bbs2-0112,
CD012216-bib-0123,"McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. ",Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium, Neurology ,2005,65,    ,['citation-journal']," McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium.  Neurology 2005;65(12):1863‐72.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/01.wnl.0000187889.17253.b1', 'https://www.ncbi.nlm.nih.gov/pubmed/16237129', ""https://scholar.google.com/scholar_lookup?title=Diagnosis+and+management+of+dementia+with+Lewy+bodies:+third+report+of+the+DLB+consortium&author=IG+McKeith&author=DW+Dickson&author=J+Lowe&author=M+Emre&author=JT+O'Brien&author=H+Feldman&publication_year=2005&hl=en""]",16237129,https://doi.org/10.1212/01.wnl.0000187889.17253.b1, McKeith 2005 ,additional,CD012216-bbs2-0113,
CD012216-bib-0124,"McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. ",Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology ,1984,34,    ,['citation-journal']," McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease.  Neurology 1984;34(7):939‐44.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.34.7.939', 'https://www.ncbi.nlm.nih.gov/pubmed/6610841', 'https://scholar.google.com/scholar_lookup?title=Clinical+diagnosis+of+Alzheimer’s+disease:+report+of+the+NINCDS‐ADRDA+Work+Group+under+the+auspices+of+Department+of+Health+and+Human+Services+Task+Force+on+Alzheimer’s+Disease+&author=GM+McKhann&author=D+Drachman&author=M+Folstein&author=R+Katzman&author=D+Price&author=EM+Stadlan&publication_year=1984&hl=en']",6610841,https://doi.org/10.1212/WNL.34.7.939, McKhann 1984 ,additional,CD012216-bbs2-0114,
CD012216-bib-0125,"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. ",The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia ,2011,7,    ,['citation-journal']," McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.  Alzheimer's & Dementia 2011;7(3):263‐9.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2011.03.005', ""https://scholar.google.com/scholar_lookup?title=The+diagnosis+of+dementia+due+to+Alzheimer's+disease:+recommendations+from+the+National+Institute+on+Aging‐Alzheimer's+Association+workgroups+on+diagnostic+guidelines+for+Alzheimer's+disease+&author=GM+McKhann&author=DS+Knopman&author=H+Chertkow&author=BT+Hyman&author=CR+Jack&author=CH+Kawas&publication_year=2011&hl=en""]",,https://doi.org/10.1016/j.jalz.2011.03.005, McKhann 2011 ,additional,CD012216-bbs2-0115,
CD012216-bib-0126,"Mitchell AJ, Shiri‐Feshki M. ",Rate of progression of mild cognitive impairment to dementia ‐ meta‐analysis of 41 robust inception cohort studies, Acta Psychiatrica Scandinavica ,2009,119,    ,['citation-journal']," Mitchell AJ, Shiri‐Feshki M. Rate of progression of mild cognitive impairment to dementia ‐ meta‐analysis of 41 robust inception cohort studies.  Acta Psychiatrica Scandinavica 2009;119(4):252‐65.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1600-0447.2008.01326.x', 'https://www.ncbi.nlm.nih.gov/pubmed/19236314', 'https://scholar.google.com/scholar_lookup?title=Rate+of+progression+of+mild+cognitive+impairment+to+dementia+‐+meta‐analysis+of+41+robust+inception+cohort+studies+&author=AJ+Mitchell&author=M+Shiri‐Feshki&publication_year=2009&hl=en']",19236314,https://doi.org/10.1111/j.1600-0447.2008.01326.x, Mitchell 2009 ,additional,CD012216-bbs2-0116,
CD012216-bib-0127,Morris JC. ,The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology ,1993,43,    ,['citation-journal'], Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.  Neurology 1993;43(11):2412‐4.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1212/WNL.43.11.2412-a', 'https://www.ncbi.nlm.nih.gov/pubmed/8232972', 'https://scholar.google.com/scholar_lookup?title=The+Clinical+Dementia+Rating+(CDR):+current+version+and+scoring+rules&author=JC+Morris&publication_year=1993&hl=en']",8232972,https://doi.org/10.1212/WNL.43.11.2412-a, Morris 1993 ,additional,CD012216-bbs2-0117,
CD012216-bib-0128,National Audit Office. ,Improving services and support for people with dementia. Report by the Comptroller and Auditor General. HC 604 Session General 2006‐2007. 4 July 2007,,,,. www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf (accessed 25th March 2015).   ,['citation-other'], National Audit Office. Improving services and support for people with dementia. Report by the Comptroller and Auditor General. HC 604 Session General 2006‐2007. 4 July 2007. www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf (accessed 25th March 2015).    ,[],,, NAO 2007 ,additional,CD012216-bbs2-0118,
CD012216-bib-0129,"Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. ",Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology ,1998,51,    ,['citation-journal']," Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.  Neurology 1998;51(6):1546‐54.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.51.6.1546', 'https://www.ncbi.nlm.nih.gov/pubmed/9855500', 'https://scholar.google.com/scholar_lookup?title=Frontotemporal+lobar+degeneration:+a+consensus+on+clinical+diagnostic+criteria&author=D+Neary&author=JS+Snowden&author=L+Gustafson&author=U+Passant&author=D+Stuss&author=S+Black&publication_year=1998&hl=en']",9855500,https://doi.org/10.1212/WNL.51.6.1546, Neary 1998 ,additional,CD012216-bbs2-0119,
CD012216-bib-0130,National Institute for Health Care Excellence. ,Dementia: supporting people with dementia and their carers in health and social care. NICE guidelines [CG42],,,,. www.nice.org.uk/guidance/cg42 (accessed 17th April 2015).   ,['citation-other'], National Institute for Health Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE guidelines [CG42]. www.nice.org.uk/guidance/cg42 (accessed 17th April 2015).    ,[],,, NICE 2006 ,additional,CD012216-bbs2-0120,
CD012216-bib-0131,"Noel‐Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. ",Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia, Alzheimer's & Dementia ,2013,9,    ,['citation-journal']," Noel‐Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia.  Alzheimer's & Dementia 2013;9(3):e96‐105.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2012.01.014', 'https://scholar.google.com/scholar_lookup?title=Systematic+review+of+the+body+of+evidence+for+the+use+of+biomarkers+in+the+diagnosis+of+dementia+&author=AH+Noel‐Storr&author=L+Flicker&author=CW+Ritchie&author=GH+Nguyen&author=T+Gupta&author=P+Wood&publication_year=2013&hl=en']",,https://doi.org/10.1016/j.jalz.2012.01.014, Noel‐Storr 2013 ,additional,CD012216-bbs2-0121,
CD012216-bib-0132,"Noel‐Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, et al. ",Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative, Neurology ,2014,83,    ,['citation-journal']," Noel‐Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, et al. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative.  Neurology 2014;83(4):364‐73.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.0000000000000621', 'https://www.ncbi.nlm.nih.gov/pubmed/24944261', 'https://scholar.google.com/scholar_lookup?title=Reporting+standards+for+studies+of+diagnostic+test+accuracy+in+dementia:+The+STARDdem+Initiative+&author=AH+Noel‐Storr&author=JM+McCleery&author=E+Richard&author=CW+Ritchie&author=L+Flicker&author=SJ+Cullum&publication_year=2014&hl=en']",24944261,https://doi.org/10.1212/WNL.0000000000000621, Noel‐Storr 2014 ,additional,CD012216-bbs2-0122,
CD012216-bib-0133,"Okello A, Edison P, Archer H, Hinz R, Fox N, Kennedy AM, et al. ",Amyloid deposition and cerebral glucose metabolism in mild cognitive impairment: a longitudinal 11C‐PIB and 18F‐FDG PET study," Journal of Neurology, Neurosurgery, and Psychiatry ",2007,78,    ,['citation-journal']," Okello A, Edison P, Archer H, Hinz R, Fox N, Kennedy AM, et al. Amyloid deposition and cerebral glucose metabolism in mild cognitive impairment: a longitudinal 11C‐PIB and 18F‐FDG PET study.  Journal of Neurology, Neurosurgery, and Psychiatry 2007;78(2):219‐20.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Amyloid+deposition+and+cerebral+glucose+metabolism+in+mild+cognitive+impairment:+a+longitudinal+11C‐PIB+and+18F‐FDG+PET+study+&author=A+Okello&author=P+Edison&author=H+Archer&author=R+Hinz&author=N+Fox&author=AM+Kennedy&publication_year=2007&hl=en'],,, Okello 2007 ,additional,CD012216-bbs2-0123,
CD012216-bib-0134,"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. ",Mild cognitive impairment: clinical characterization and outcome, Archives of Neurology ,1999,56,    ,['citation-journal']," Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome.  Archives of Neurology 1999;56(3):303‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archneur.56.3.303', 'https://www.ncbi.nlm.nih.gov/pubmed/10190820', 'https://scholar.google.com/scholar_lookup?title=Mild+cognitive+impairment:+clinical+characterization+and+outcome&author=RC+Petersen&author=GE+Smith&author=SC+Waring&author=RJ+Ivnik&author=EG+Tangalos&author=E+Kokmen&publication_year=1999&hl=en']",10190820,https://doi.org/10.1001/archneur.56.3.303, Petersen 1999 ,additional,CD012216-bbs2-0124,
CD012216-bib-0135,Petersen RC. ,Mild cognitive impairment as a diagnostic entity, Journal of Internal Medicine ,2004,256,    ,['citation-journal'], Petersen RC. Mild cognitive impairment as a diagnostic entity.  Journal of Internal Medicine 2004;256(3):183‐94.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1111/j.1365-2796.2004.01388.x', 'https://www.ncbi.nlm.nih.gov/pubmed/15324362', 'https://scholar.google.com/scholar_lookup?title=Mild+cognitive+impairment+as+a+diagnostic+entity&author=RC+Petersen&publication_year=2004&hl=en']",15324362,https://doi.org/10.1111/j.1365-2796.2004.01388.x, Petersen 2004 ,additional,CD012216-bbs2-0125,
CD012216-bib-0136,"Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. ",Mild cognitive impairment: ten years later, Archives of Neurology ,2009,66,    ,['citation-journal']," Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later.  Archives of Neurology 2009;66(12):1447‐55.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archneurol.2009.266', 'https://www.ncbi.nlm.nih.gov/pubmed/20008648', 'https://scholar.google.com/scholar_lookup?title=Mild+cognitive+impairment:+ten+years+later&author=RC+Petersen&author=RO+Roberts&author=DS+Knopman&author=BF+Boeve&author=YE+Geda&author=RJ+Ivnik&publication_year=2009&hl=en']",20008648,https://doi.org/10.1001/archneurol.2009.266, Petersen 2009 ,additional,CD012216-bbs2-0126,
CD012216-bib-0137,"Quinn TJ, Fearon P, Noel‐Storr AH, Young C, McShane R, Stott DJ. ",Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Quinn TJ, Fearon P, Noel‐Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations.  Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD010079.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010079.pub2', 'https://scholar.google.com/scholar_lookup?title=Informant+Questionnaire+on+Cognitive+Decline+in+the+Elderly+(IQCODE)+for+the+diagnosis+of+dementia+within+community+dwelling+populations+&author=TJ+Quinn&author=P+Fearon&author=AH+Noel‐Storr&author=C+Young&author=R+McShane&author=DJ+Stott&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD010079.pub2, Quinn 2014 ,additional,CD012216-bbs2-0127,
CD012216-bib-0138,"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. ",Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain ,2011,134,    ,['citation-journal']," Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.  Brain 2011;134(Pt 9):2456‐77.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/brain/awr179', 'https://www.ncbi.nlm.nih.gov/pubmed/21810890', 'https://scholar.google.com/scholar_lookup?title=Sensitivity+of+revised+diagnostic+criteria+for+the+behavioural+variant+of+frontotemporal+dementia+&author=K+Rascovsky&author=JR+Hodges&author=D+Knopman&author=MF+Mendez&author=JH+Kramer&author=J+Neuhaus&publication_year=2011&hl=en']",21810890,https://doi.org/10.1093/brain/awr179, Rascovsky 2011 ,additional,CD012216-bbs2-0128,
CD012216-bib-0139,"The Nordic Cochrane Centre, The Cochrane Collaboration. ",Review Manager,,2014,,.   ,['citation-other']," The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.    ",[],,, Review Manager 2014 [Computer program] ,additional,CD012216-bbs2-0129,
CD012216-bib-0140,"Richard E, Schmand B, Eikelenboom P, Westendorp RG, Van Gool WA. ",The Alzheimer myth and biomarker research in dementia, Journal of Alzheimer's Disease: JAD ,2012,31,    ,['citation-journal']," Richard E, Schmand B, Eikelenboom P, Westendorp RG, Van Gool WA. The Alzheimer myth and biomarker research in dementia.  Journal of Alzheimer's Disease: JAD 2012;31(Suppl 3):S203‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3233/JAD-2012-112216', 'https://www.ncbi.nlm.nih.gov/pubmed/22810091', 'https://scholar.google.com/scholar_lookup?title=The+Alzheimer+myth+and+biomarker+research+in+dementia&author=E+Richard&author=B+Schmand&author=P+Eikelenboom&author=RG+Westendorp&author=WA+Gool&publication_year=2012&hl=en']",22810091,https://doi.org/10.3233/JAD-2012-112216, Richard 2012 ,additional,CD012216-bbs2-0130,
CD012216-bib-0141,"Ritchie C, Smailagic N, Ladds EC, Noel‐Storr AH, Ukoumunne O, Martin S. ",CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2013,,    ,['citation-journal']," Ritchie C, Smailagic N, Ladds EC, Noel‐Storr AH, Ukoumunne O, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010803]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010803', ""https://scholar.google.com/scholar_lookup?title=CSF+tau+and+the+CSF+tau/ABeta+ratio+for+the+diagnosis+of+Alzheimer's+disease+dementia+and+other+dementias+in+people+with+mild+cognitive+impairment+(MCI)+&author=C+Ritchie&author=N+Smailagic&author=EC+Ladds&author=AH+Noel‐Storr&author=O+Ukoumunne&author=S+Martin&publication_year=2013&hl=en""]",,https://doi.org/10.1002/14651858.CD010803, Ritchie 2013 ,additional,CD012216-bbs2-0131,
CD012216-bib-0142,"Ritchie C, Smailagic N, Noel‐Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. ",Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Ritchie C, Smailagic N, Noel‐Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD008782.pub4]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD008782.pub4', 'https://www.ncbi.nlm.nih.gov/pubmed/24913723', ""https://scholar.google.com/scholar_lookup?title=Plasma+and+cerebrospinal+fluid+amyloid+beta+for+the+diagnosis+of+Alzheimer's+disease+dementia+and+other+dementias+in+people+with+mild+cognitive+impairment+(MCI)+&author=C+Ritchie&author=N+Smailagic&author=AH+Noel‐Storr&author=Y+Takwoingi&author=L+Flicker&author=SE+Mason&publication_year=2014&hl=en""]",24913723,https://doi.org/10.1002/14651858.CD008782.pub4, Ritchie 2014 ,additional,CD012216-bbs2-0132,
CD012216-bib-0143,"Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. ",Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop, Neurology ,1993,43,    ,['citation-journal']," Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop.  Neurology 1993;43(2):250‐60.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.43.2.250', 'https://www.ncbi.nlm.nih.gov/pubmed/8094895', 'https://scholar.google.com/scholar_lookup?title=Vascular+dementia:+diagnostic+criteria+for+research+studies.+Report+of+the+NINDS‐AIREN+International+Workshop+&author=GC+Román&author=TK+Tatemichi&author=T+Erkinjuntti&author=JL+Cummings&author=JC+Masdeu&author=JH+Garcia&publication_year=1993&hl=en']",8094895,https://doi.org/10.1212/WNL.43.2.250, Román 1993 ,additional,CD012216-bbs2-0133,
CD012216-bib-0144,"Royall DR, Palmer RF. ",The temporospatial evolution of neuritic plaque‐related and independent tauopathies: implications for dementia staging, Journal of Alzheimer’s Disease ,2014,40,    ,['citation-journal']," Royall DR, Palmer RF. The temporospatial evolution of neuritic plaque‐related and independent tauopathies: implications for dementia staging.  Journal of Alzheimer’s Disease 2014;40(3):541‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3233/JAD-131733', 'https://www.ncbi.nlm.nih.gov/pubmed/24577462', 'https://scholar.google.com/scholar_lookup?title=The+temporospatial+evolution+of+neuritic+plaque‐related+and+independent+tauopathies:+implications+for+dementia+staging+&author=DR+Royall&author=RF+Palmer&publication_year=2014&hl=en']",24577462,https://doi.org/10.3233/JAD-131733, Royall 2014 ,additional,CD012216-bbs2-0134,
CD012216-bib-0145,"Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study. ","Age, neuropathology, and dementia", The New England Journal of Medicine ,2009,360,    ,['citation-journal']," Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia.  The New England Journal of Medicine 2009;360(22):2302‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1056/NEJMoa0806142', 'https://www.ncbi.nlm.nih.gov/pubmed/19474427', 'https://scholar.google.com/scholar_lookup?title=Age,+neuropathology,+and+dementia&author=GM+Savva&author=SB+Wharton&author=PG+Ince&author=G+Forster&author=FE+Matthews&author=C+Brayne&publication_year=2009&hl=en']",19474427,https://doi.org/10.1056/NEJMoa0806142, Savva 2009 ,additional,CD012216-bbs2-0135,
CD012216-bib-0146,"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. ",Mixed brain pathologies account for most dementia cases in community‐dwelling older persons, Neurology ,2007,69,    ,['citation-journal']," Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community‐dwelling older persons.  Neurology 2007;69(24):2197‐204.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/01.wnl.0000271090.28148.24', 'https://www.ncbi.nlm.nih.gov/pubmed/17568013', 'https://scholar.google.com/scholar_lookup?title=Mixed+brain+pathologies+account+for+most+dementia+cases+in+community‐dwelling+older+persons+&author=JA+Schneider&author=Z+Arvanitakis&author=W+Bang&author=DA+Bennett&publication_year=2007&hl=en']",17568013,https://doi.org/10.1212/01.wnl.0000271090.28148.24, Schneider 2007 ,additional,CD012216-bbs2-0136,
CD012216-bib-0147,"Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. ",The neuropathology of probable Alzheimer disease and mild cognitive impairment, Annals of neurology ,2009,66,    ,['citation-journal']," Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment.  Annals of neurology 2009;66(2):200‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/ana.21706', 'https://www.ncbi.nlm.nih.gov/pubmed/19743450', 'https://scholar.google.com/scholar_lookup?title=The+neuropathology+of+probable+Alzheimer+disease+and+mild+cognitive+impairment&author=JA+Schneider&author=Z+Arvanitakis&author=SE+Leurgans&author=DA+Bennett&publication_year=2009&hl=en']",19743450,https://doi.org/10.1002/ana.21706, Schneider 2009 ,additional,CD012216-bbs2-0137,
CD012216-bib-0148,"Seitz DP, Fage BA, Chan CCH, Gill SS, Herrmann N, Smailagic N, et al. ",Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Seitz DP, Fage BA, Chan CCH, Gill SS, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting.  Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011415]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011415', 'https://www.ncbi.nlm.nih.gov/pubmed/24526393', 'https://scholar.google.com/scholar_lookup?title=Mini‐Cog+for+the+diagnosis+of+Alzheimer’s+disease+dementia+and+other+dementias+within+a+primary+care+setting+&author=DP+Seitz&author=BA+Fage&author=CCH+Chan&author=SS+Gill&author=N+Herrmann&author=N+Smailagic&publication_year=2014&hl=en']",24526393,https://doi.org/10.1002/14651858.CD011415, Seitz 2014 ,additional,CD012216-bbs2-0138,
CD012216-bib-0149,"Selkoe DJ, Hardy J. ",The amyloid hypothesis of Alzheimer's disease at 25 years, EMBO Molecular Medicine ,2016,8,    ,['citation-journal']," Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years.  EMBO Molecular Medicine 2016;8(6):595‐608.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.15252/emmm.201606210', 'https://www.ncbi.nlm.nih.gov/pubmed/27025652', ""https://scholar.google.com/scholar_lookup?title=The+amyloid+hypothesis+of+Alzheimer's+disease+at+25+years&author=DJ+Selkoe&author=J+Hardy&publication_year=2016&hl=en""]",27025652,https://doi.org/10.15252/emmm.201606210, Selkoe 2016 ,additional,CD012216-bbs2-0139,
CD012216-bib-0150,"Serrano‐Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. ",Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center, Journal of Neuropathology and Experimental Neurology ,2013,72,    ,['citation-journal']," Serrano‐Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center.  Journal of Neuropathology and Experimental Neurology 2013;72(12):1182‐92.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/NEN.0000000000000016', 'https://www.ncbi.nlm.nih.gov/pubmed/24226270', 'https://scholar.google.com/scholar_lookup?title=Examination+of+the+clinicopathologic+continuum+of+Alzheimer+disease+in+the+autopsy+cohort+of+the+National+Alzheimer+Coordinating+Center+&author=A+Serrano‐Pozo&author=J+Qian&author=SE+Monsell&author=MP+Frosch&author=RA+Betensky&author=BT+Hyman&publication_year=2013&hl=en']",24226270,https://doi.org/10.1097/NEN.0000000000000016, Serrano‐Pozo 2013 ,additional,CD012216-bbs2-0140,
CD012216-bib-0151,"Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, et al. ",PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F‐AV‐133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders, BMC neurology [electronic resource] ,2014,14,    ,['citation-journal']," Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F‐AV‐133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.  BMC neurology [electronic resource] 2014;14:1‐9.    Link to article     Google Scholar     ","['https://doi.org/10.1186/1471-2377-14-79', ""https://scholar.google.com/scholar_lookup?title=PET+imaging+of+amyloid+with+Florbetapir+F+18+and+PET+imaging+of+dopamine+degeneration+with+18F‐AV‐133+(florbenazine)+in+patients+with+Alzheimer's+disease+and+Lewy+body+disorders+&author=A+Siderowf&author=MJ+Pontecorvo&author=HA+Shill&author=MA+Mintun&author=A+Arora&author=AD+Joshi&publication_year=2014&hl=en""]",,https://doi.org/10.1186/1471-2377-14-79, Siderowf 2014 ,additional,CD012216-bbs2-0141,
CD012216-bib-0152,"Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. ",18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2015,,    ,['citation-journal']," Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010632.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD010632.pub2', 'https://scholar.google.com/scholar_lookup?title=18F‐FDG+PET+for+the+early+diagnosis+of+Alzheimer’s+disease+dementia+and+other+dementias+in+people+with+mild+cognitive+impairment+(MCI)+&author=N+Smailagic&author=M+Vacante&author=C+Hyde&author=S+Martin&author=O+Ukoumunne&author=C+Sachpekidis&publication_year=2015&hl=en']",,https://doi.org/10.1002/14651858.CD010632.pub2, Smailagic 2015 ,additional,CD012216-bbs2-0142,
CD012216-bib-0153,"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. ",Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia: the Journal of the Alzheimer's Association ,2011,7,    ,['citation-journal']," Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.  Alzheimer's & Dementia: the Journal of the Alzheimer's Association 2011;7(3):280‐92.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jalz.2011.03.003', 'https://www.ncbi.nlm.nih.gov/pubmed/21514248', ""https://scholar.google.com/scholar_lookup?title=Toward+defining+the+preclinical+stages+of+Alzheimer's+disease:+recommendations+from+the+National+Institute+on+Aging‐Alzheimer's+Association+workgroups+on+diagnostic+guidelines+for+Alzheimer's+disease+&author=RA+Sperling&author=PS+Aisen&author=LA+Beckett&author=DA+Bennett&author=S+Craft&author=AM+Fagan&publication_year=2011&hl=en""]",21514248,https://doi.org/10.1016/j.jalz.2011.03.003, Sperling 2011 ,additional,CD012216-bbs2-0143,
CD012216-bib-0154,"Visser PJ, Kester A, Jolles J, Verhey F. ",Ten‐year risk of dementia in subjects with mild cognitive impairment, Neurology ,2006,67,    ,['citation-journal']," Visser PJ, Kester A, Jolles J, Verhey F. Ten‐year risk of dementia in subjects with mild cognitive impairment.  Neurology 2006;67(7):1201‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/01.wnl.0000238517.59286.c5', 'https://www.ncbi.nlm.nih.gov/pubmed/17030753', 'https://scholar.google.com/scholar_lookup?title=Ten‐year+risk+of+dementia+in+subjects+with+mild+cognitive+impairment&author=PJ+Visser&author=A+Kester&author=J+Jolles&author=F+Verhey&publication_year=2006&hl=en']",17030753,https://doi.org/10.1212/01.wnl.0000238517.59286.c5, Visser 2006 ,additional,CD012216-bbs2-0144,
CD012216-bib-0155,White L. ,Brain lesions at autopsy in older Japanese‐American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu‐Asia aging study, Journal of Alzheimer's Disease: JAD ,2009,18,    ,['citation-journal'], White L. Brain lesions at autopsy in older Japanese‐American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu‐Asia aging study.  Journal of Alzheimer's Disease: JAD 2009;18(3):713‐25.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.3233/JAD-2009-1178', 'https://www.ncbi.nlm.nih.gov/pubmed/19661625', 'https://scholar.google.com/scholar_lookup?title=Brain+lesions+at+autopsy+in+older+Japanese‐American+men+as+related+to+cognitive+impairment+and+dementia+in+the+final+years+of+life:+a+summary+report+from+the+Honolulu‐Asia+aging+study+&author=L+White&publication_year=2009&hl=en']",19661625,https://doi.org/10.3233/JAD-2009-1178, White 2009 ,additional,CD012216-bbs2-0145,
CD012216-bib-0156,"Whiting PF, Rutjes AWS, Westwood ME, Mallet S, Deeks JJ, Reitsma JB. ",QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies, Annals of Internal Medicine ,2011,155,    ,['citation-journal']," Whiting PF, Rutjes AWS, Westwood ME, Mallet S, Deeks JJ, Reitsma JB. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies.  Annals of Internal Medicine 2011;155(8):529‐36.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.7326/0003-4819-155-8-201110180-00009', 'https://www.ncbi.nlm.nih.gov/pubmed/22007046', 'https://scholar.google.com/scholar_lookup?title=QUADAS‐2:+a+revised+tool+for+the+quality+assessment+of+diagnostic+accuracy+studies&author=PF+Whiting&author=AWS+Rutjes&author=ME+Westwood&author=S+Mallet&author=JJ+Deeks&author=JB+Reitsma&publication_year=2011&hl=en']",22007046,https://doi.org/10.7326/0003-4819-155-8-201110180-00009, Whiting 2011 ,additional,CD012216-bbs2-0146,
CD012216-bib-0157,"World Health Organization, Alzheimer's Disease International. ",Dementia: a public health priority. 2012,,,,". http://www.who.int/mental_health/publications/dementia_report_2012/en/. World Health Organization, (accessed 23th September 2015).   ",['citation-other']," World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. 2012. http://www.who.int/mental_health/publications/dementia_report_2012/en/. World Health Organization, (accessed 23th September 2015).    ",[],,, WHO 2012 ,additional,CD012216-bbs2-0147,
CD012216-bib-0158,"Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. ","Mild cognitive impairment‐‐beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment", Journal of Internal Medicine ,2004,256,    ,['citation-journal']," Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment‐‐beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.  Journal of Internal Medicine 2004;256(3):240‐6.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1365-2796.2004.01380.x', 'https://www.ncbi.nlm.nih.gov/pubmed/15324367', 'https://scholar.google.com/scholar_lookup?title=Mild+cognitive+impairment‐‐beyond+controversies,+towards+a+consensus:+report+of+the+International+Working+Group+on+Mild+Cognitive+Impairment+&author=B+Winblad&author=K+Palmer&author=M+Kivipelto&author=V+Jelic&author=L+Fratiglioni&author=LO+Wahlund&publication_year=2004&hl=en']",15324367,https://doi.org/10.1111/j.1365-2796.2004.01380.x, Winblad 2004 ,additional,CD012216-bbs2-0148,
CD012216-bib-0159,"Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DL, Alzheimer's Disease Neuroimaging Initiative. ",Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration, Neurology ,2016,87,    ,['citation-journal']," Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DL, Alzheimer's Disease Neuroimaging Initiative. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration.  Neurology 2016;87(12):1235‐41.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1212/WNL.0000000000003126', 'https://www.ncbi.nlm.nih.gov/pubmed/27558378', 'https://scholar.google.com/scholar_lookup?title=Enrichment+of+clinical+trials+in+MCI+due+to+AD+using+markers+of+amyloid+and+neurodegeneration&author=R+Wolz&author=AJ+Schwarz&author=KR+Gray&author=P+Yu&author=DL+Hill&publication_year=2016&hl=en']",27558378,https://doi.org/10.1212/WNL.0000000000003126, Wolz 2016 ,additional,CD012216-bbs2-0149,
CD012216-bib-0160,"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. ",In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F‐AV‐45 (Florbetapir F18), Journal of Nuclear Medicine ,2010,51,    ,['citation-journal']," Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F‐AV‐45 (Florbetapir F18).  Journal of Nuclear Medicine 2010;51(6):913‐20.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.2967/jnumed.109.069088', 'https://www.ncbi.nlm.nih.gov/pubmed/20501908', 'https://scholar.google.com/scholar_lookup?title=In+vivo+imaging+of+amyloid+deposition+in+Alzheimer+disease+using+the+radioligand+18F‐AV‐45+(Florbetapir+F18)+&author=DF+Wong&author=PB+Rosenberg&author=Y+Zhou&author=A+Kumar&author=V+Raymont&author=HT+Ravert&publication_year=2010&hl=en']",20501908,https://doi.org/10.2967/jnumed.109.069088, Wong 2010 ,additional,CD012216-bbs2-0150,
CD012216-bib-0161,"Zhang S, Smailagic N, Hyde C, Noel‐Storr AH, Takwoingi Y, McShane R, et al. ",11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Zhang S, Smailagic N, Hyde C, Noel‐Storr AH, Takwoingi Y, McShane R, et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI).  Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=11C‐PIB‐PET+for+the+early+diagnosis+of+Alzheimer’s+disease+dementia+and+other+dementias+in+people+with+mild+cognitive+impairment+(MCI)+&author=S+Zhang&author=N+Smailagic&author=C+Hyde&author=AH+Noel‐Storr&author=Y+Takwoingi&author=R+McShane&publication_year=2014&hl=en'],,, Zhang 2014 ,additional,CD012216-bbs2-0151,
